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Abstract
Despite much progress in our understanding of the essence of cancer, remarkable 
advances in methods for early diagnosis, the expanding array of antineoplastic drugs 
and treatment modalities, as well as important refinements in their use, this disease 
is among the leading causes of morbidity and mortality in many parts of the world. 
In fact, the next decade is anticipated to bring over 20 million new cases per year 
globally, about half of whom will die from their disease. This indicates a need for 
better strategies to deal with cancer. One way to go forward is to draw lessons from 
ancient ethnopharmacological wisdom and to evaluate the plant biodiversity for 
compounds with potential antineoplastic activity. This approach has already yielded 
many breakthrough cytotoxic drugs such as vincristine, etoposide, paclitaxel, and 
irinotecan. The Republic of Suriname (South America), renowned for its pristine 
and highly biodiverse rain forests as well as its ethnic, cultural, and ethnopharmaco-
logical diversity, could also contribute to these developments. This chapter addresses 
the cancer problem throughout the world and in Suriname, extensively deals with 
nine plants used for treating cancer in the country, and concludes with their pros-
pects in anticancer drug discovery and development programs.
Keywords: cancer, Suriname, medicinal plants, traditional uses, phytochemistry, 
pharmacology, anticancer activity
1. Introduction
1.1 Generalities
Cancer is a generic term to describe over 200 distinct disease forms that, none-
theless, share three distinguishing characteristics, namely uncontrolled cellular 
proliferation, invasion of the abnormal cells into adjacent tissues, and their spread 
to distant organs via blood and lymph vessels [1]. The biological events funda-
mental to the development of cancer involve the transformation of normal cells 
Pharmacognosy - Medicinal Plants
2
to a precancerous lesion which subsequently progresses to a malignant tumor in a 
multistage process [1]. These changes are the result of the interaction between an 
individual’s genetic make-up and external agents including physical, chemical, and 
biological carcinogens [2].
Recognized physical carcinogens are ultraviolet and ionizing radiation which 
have been linked to skin cancer as well as leukemia and a number of solid tumors, 
respectively [2]. Well-studied chemical carcinogens are asbestos that has mainly 
been associated with lung cancer and mesothelioma; components of tobacco 
smoke which have been linked not only to breast and lung cancer but also to a 
host of other malignancies; aflatoxins produced by certain molds in improperly 
stored staple commodities which have been related to liver cancer; and the drink-
ing water contaminant arsenic that has particularly been associated with lung, 
bladder, and kidney cancer [2]. Examples of biological carcinogens are the human 
papillomavirus, the hepatitis B virus, the hepatitis C virus, and the Epstein-Barr 
virus, the causative factors of cervical cancer, liver cancer, and certain lymphomas, 
respectively; the stomach bacterium Helicobacter pylori that has been implicated in 
the development of stomach cancer; and certain fish-parasitic flatworms associated 
with cholangiocarcinoma and urinary bladder cancer [2].
Molecular insights have revealed that the development of cancer—including its 
capacity to proliferate in an uncontrolled fashion, escape apoptosis, invade neigh-
boring tissues, and disseminate to distant organs—involves aberrations in molecu-
lar networks that include oncogenes, tumor suppressor genes, and repair genes [1]. 
These changes occur in a multistep manner and often take place over many years 
[1]. This is an important reason that cancer usually manifests at older age, when suf-
ficient carcinogenic mutations have accumulated to cause cancer and innate defense 
and cellular repair mechanisms have become less effective [1].
1.2 Worldwide epidemiology
According to GLOBOCAN 2018 estimates of cancer incidence and mortality 
produced by the International Agency for Research on Cancer, cancer will represent 
the leading cause of death throughout the world in the twenty-first century [3]. In 
2018, there were an estimated 18.1 million new cancer cases and 9.6 million cancer 
deaths globally [3]. Lung cancer and female breast cancer were the most commonly 
diagnosed malignancy (each 11.6% of total overall cases), followed by cancer of 
colon and rectum (10.2%), prostate (7.1%), stomach (5.7%), and liver (4.7%) [3]. 
The most deadly cancers in that year were lung, colorectal, stomach, liver, and breast 
cancer accounting for 18.4, 9.2, 8.2, 8.2, and 6.6%, respectively, of the total number 
of cancer fatalities [3]. The most frequent cancers in males were lung, prostate, 
colorectal, stomach, and liver cancer with incidence rates of 14.5, 13.5, 10.9, 7.2, and 
6.3%, respectively, and mortality rates of 22.0, 6.7, 9.0, 9.5, and 10.2%, respectively 
[3]. And in females, the most common cancers were those of the breast, colon and 
rectum, lung, and cervix uteri, with incidence rates of 24.2, 9.5, 8.4, and 6.6%, 
respectively, and mortality rates of 15.0, 9.5, 13.8, and 7.5%, respectively [3].
There were substantial variations among countries with respect to the most fre-
quently diagnosed cancers and the leading causes of cancer death [3]. For instance, 
for many cancers, incidence rates were generally two- to threefold higher in 
industrialized countries than in transitioning economies [3]. However, differences 
in mortality were smaller, as relatively more patients in developing countries died 
from their disease, probably because of low screening rates as well as less advanced 
screening services and diagnostic methods in these regions [3]. Furthermore, 
cancers related to a westernized lifestyle such as lung, breast, and colorectal 
cancer were (much) more common in industrialized regions than in developing/
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transitioning regions, even though these neoplasms were among the most com-
mon malignancies in both regions [3]. On the other hand, oral cancer and cervical 
cancer were much more frequent in (certain) developing/transitioning countries 
than in industrialized countries [3]. These differences are probably for an important 
part attributable to differences in associated risk factors and screening facilities, 
respectively, resulting in the former malignancy accounting for almost 50% to the 
burden of cancer in south-central Asia [4] and the latter occurring at incidence 
rates between 13.0 and 43.1 per 100,000 in Central America, South America, and 
the Caribbean, as well as in the parts of Africa [5].
1.3 Treatment modalities
The treatment modalities for cancer depend on the type of cancer as well as 
its stage and grade [6]. Some cases require only one form of treatment, but most 
patients need a combination of therapeutic modalities such as surgery with che-
motherapy and/or radiation therapy. Surgery is applied for removing localized 
solid tumors or debulking large solid tumors in order to improve the efficacy of, for 
instance, chemotherapy [6]. Radiation therapy—external beam radiation therapy, 
brachytherapy, or systemic radioisotope therapy—uses high doses of radiation to 
kill cancer cells by damaging their DNA [6]. Chemotherapy is a systemic treatment 
with mostly combinations of antineoplastic drugs and is intended to kill cancer cells 
by stopping or slowing their growth or division, but it is also applied as an adjuvant 
to prevent disease recurrence after surgery or radiation therapy and as a neoadju-
vant therapy to decrease the size of a tumor before surgery or radiation therapy [6].
Other cancer treatment modalities are immunotherapy, hormonal therapy, and 
angiosuppressive therapy. Immunotherapy can make use of adoptive cell transfer 
involving the infusion of engineered autologous or allogeneic T cells into a patient 
which can attack the cancer directly; monoclonal antibodies directed at cancer cell-
specific antigens; or immunomodulating substances such as cytokines and Bacillus 
Calmette-Guérin vaccine which stimulate the immune system in a more general way 
[6]. Hormonal therapy slows or stops the growth of hormone-dependent tumors 
such as breast and prostate cancers, or reduces or prevents the symptoms in patients 
suffering from these cancers who do not qualify for surgery or radiation therapy 
[6]. Hormonal therapy can also be used in the adjuvant or neoadjuvant setting [6]. 
Angiosuppressive or antiangiogenic therapy interrupts the angiogenic signals that a 
tumor emits to its surroundings for recruiting a blood supply and causes tumors to 
shrink [6].
Despite this respectable array of antineoplastic agents and therapeutic modali-
ties most cancers remain fatal, particularly when detected at an advanced stage. 
This implies a need for more efficacious forms of treatment of neoplastic disease. 
Many efforts are being dedicated to this goal, including improved early diagnosis, 
the development of highly specific targeted therapies, and the identification of 
more efficacious antineoplastic drugs. It is generally agreed that the application of 
ancient wisdom and folk medicine represents an important strategy to discover and 
develop new anticancer drugs [7–10]. This approach has led to breakthrough anti-
cancer drugs such as the tubulin-interfering agents vincristine from the periwinkle 
plant Catharanthus roseus (L.) G. Don (Apocynaceae) [11] and paclitaxel from the 
Pacific yew Taxus brevifolia Peattie 1950 (Taxaceae) [12]; the topoisomerase I and II 
inhibitors irinotecan [13] and etoposide [14], respectively, from Podophyllum plant 
species (Berberidaceae) and the Chinese happy tree Camptotheca acuminata Decne. 
(Nyssaceae), respectively; as well as a host of other plant-derived compounds [7, 
10]. Notably, almost half of the anticancer drugs that have been granted approval in 
the United States of America between 1981 and 2014 were from natural origin [9].
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So far, only a relative handful of the plant kingdom has been evaluated for 
pharmacologically active plant substances with potential efficacy against cancer. 
Therefore, it is likely that further exploration of the rain forests along with other 
less explored environments such as deserts, tundras, as well as freshwater and 
marine ecosystems [15], will help identify many structurally novel and mecha-
nistically unique compounds for fighting cancer. This chapter first reviews a few 
aspects of cancer throughout the world, then focuses on cancer in the Republic 
of Suriname, subsequently addresses in detail nine medicinal plants that are used 
for treating cancer in the country, and concludes with some remarks about their 
potential usefulness against this disease.
2. Background on Suriname
2.1 Geography, population, demographics, and economy
The Republic of Suriname is situated in the north-eastern part of South America 
adjacent to the Atlantic Ocean and has a land area of roughly 165,000 km2 (Figure 1). 
The population of about 570,000 is among the ethnically most varied in the world, 
comprising Amerindians, the original inhabitants; Maroons, the immediate descen-
dants of enslaved Africans shipped from western Africa between the seventeenth 
and the nineteenth century; Creoles, a generic term referring to anyone having one 
or more African ancestors; the descendants from indentured laborers attracted from 
China, India, and Java (Indonesia) between the second half of the nineteenth cen-
tury and the first half of the twentieth century; as well as immigrants from various 
European, South American, and Caribbean countries [16].
Figure 1. 
Location of Suriname with respect to its neighboring countries French Guiana, Brazil, and Guyana, as well as 
its position in South America (insert) (from: https://goo.gl/images/F77jgS).
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Suriname can be characterized as a demographically transitioning country with 
declining mortality and infertility rates as well as a growing and aging population. 
These changes are for an important attributable to considerable progress in health 
care, nutrition, sanitation, and drinking water quality; the eradication of various 
infectious diseases; as well as improvements in average living and working condi-
tions, education, and income [17, 18]. The result was a decline of the death rate 
from 24 per 1000 in 1923 to 6 per 1000 in 2011 and the attainment of an average life 
expectancy of 70 years in 2011 [17].
The country’s most important economic means of support are crude oil drilling 
as well as gold and bauxite mining [19]. These activities, together with agriculture, 
fisheries, forestry, and ecotourism, have substantially contributed to Suriname’s 
gross domestic income (GDI) in 2014 of USD 5.21 billion and the average per capita 
income in that year of USD 9325 [19]. This positions Suriname on the World Bank’s 
list of upper-middle income economies [20].
2.2 Health care
Suriname spends about 5.7% of its GDI—which amounted to USD 589 per capita 
in 2014—to health care [21]. This sum covers the health costs for the economically 
weakest individuals; insurance for government employees and employees of gov-
ernment-related companies; import and distribution of essential pharmaceuticals; 
vaccination programs; maternal and child health care; programs to fight parasitic 
and microbial diseases; dental care for schoolchildren; services for dermatological 
diseases, sexually transmitted diseases, and HIV/AIDS; as well as a Kidney Dialyses 
Center and a Blood Bank [21].
Primary health care in Suriname is offered by the government-subsidized 
Regional Health Services and Medical Mission, as well as approximately 250 general 
practitioners. The Regional Health Services run 43 community health centers 
staffed with physicians and nurses, covers the entire coastal area, and offers basic 
laboratory testing as well as curative and preventive services including cervical 
cancer screening and dental, prenatal, and obstetric care. The Medical Mission is 
a nongovernmental organization that provides health services to people living in 
Suriname’s hinterland. The clinics are staffed with community health workers who 
are supervised by general practitioners who travel back and forth on a regular basis.
Secondary care is provided by two private and two government-supported hospi-
tals in Paramaribo and one public hospital in the western district of Nickerie. Medical 
emergencies can turn around-the-clock to the First-aid Stations of the Academic 
Hospital Paramaribo and the Saint Vincentius Hospital Suriname. The Academic 
Hospital Paramaribo also functions as training facility for both general practitioners 
and medical specialists. All hospitals have modern clinical laboratory facilities as well 
as radiology services at their disposal. There are, in addition, four private clinical labo-
ratories and three private radiology clinics. Diagnostic imaging including computed 
tomography and magnetic resonance imaging is possible at two private clinics and the 
Academic Hospital Paramaribo. This hospital also provides tertiary care at a Thorax 
Center, a Neurology High-Care Unit, a Neonatal Care Unit, and a Radiotherapy Center.
3. Cancer in Suriname
3.1 Epidemiology
As in many other low- and middle-income countries, there is no population-
based cancer registry in Suriname. The occurrence of cancer in the country is 
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estimated from data on the histopathologically confirmed cases at the Pathologic 
Anatomical Laboratory of the Academic Hospital Paramaribo that functions as the 
country’s cancer-based registry. This institution reported for 2014 a crude incidence 
rate of 133 per 100,000 population with the most common cancers being breast, 
colorectal, prostate, and cervical cancer [22]. An earlier publication [23] mentioned 
an average of 70 per 100,000 population for the period 1980–2000, suggesting an 
almost twofold increase in the occurrence of cancer in Suriname since the turn of 
the century.
Cancer mortality in Suriname has been registered since 1958. In the period 
between 1962 and 1970, the average death rate due to cancer was 60 per 100,000 
per year [24]. This figure had risen to approximately 72 in 2011, ranking cancer as 
the second most common cause of mortality in the country, after cardiovascular 
diseases [25]. The top five causes of cancer mortality in that year were prostate, 
lung, rectum-sigmoid, female breast, and cervical cancer [25]. Most of the fatalities 
in females were attributable to breast and cervical cancer, while prostate cancer was 
the leading cause of cancer death in males [25].
3.2 Allopathic forms of cancer treatment in Suriname
Suriname has no national guidelines for the screening, diagnosis, and treatment 
of cancer, and structured screening programs for breast, cervical, and colon cancer 
are nonexistent. For these reasons, a comprehensive national cancer control plan 
has been developed [22] that will be executed in the short term by the Ministry of 
Health.
Still, primary prevention programs such as mandatory vaccination against the 
hepatitis B virus (since 2011) and the availability of a HPV vaccine for young girls 
(implemented in 2013) may help reduce the cancer burden in the country. This 
may also be achieved by early detection services such as screening for cervical and 
breast cancer, even though these facilities are in general utilized on an ad hoc basis. 
Cervical cancer screening occurs upon referral and is done at the Lobi Foundation, 
a nongovernmental organization for reproductive preventive services, using cytol-
ogy (Pap smear) or visual inspection with acetic acid. Unfortunately, the coverage 
of this program is below 20% and thus has probably little impact on cervical cancer 
mortality [26]. Mammography, breast ultrasound, and fine needle aspiration for the 
assessment of breast lesions are since 2009 possible at two private clinics and two 
hospitals. Stereotactic (mammogram-guided) breast biopsy has been available since 
2018 at the Academic Hospital Paramaribo. Cancer-specific evaluations such as 
testing for hormone receptors and tumor markers, are carried out at the Pathologic 
Anatomical Laboratory of this hospital.
Surgery, radiation therapy, and chemotherapy as standard therapeutic modali-
ties for cancer are all available in Suriname. Surgical treatment is offered by all four 
hospitals in Paramaribo. Radiation therapy has been available since 2012 and is 
performed by two radiation oncologists. Chemotherapy is delivered by two oncolo-
gists and two gynecologic oncologists. If diagnostic or therapeutic services are not 
available in Suriname, patients can be transferred to health centers abroad provided 
that they have a good prognosis and are younger than 70 years. More than half of 
the selected patients are treated in Bogotá, Columbia. All costs are covered by the 
Surinamese Ministry of Health through the State Health Foundation [21].
3.3 Traditional forms of cancer treatment in Suriname
All ethnic groups in Suriname have preserved their own specific identity 
including their particular forms of traditional medicine, probably as a means of 
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strengthening the ethnic identity after their relocation to their new homeland [27, 
28]. Not surprisingly, the use of various traditional medicinal systems—involv-
ing, among others, Indigenous, African, and Chinese traditional medicine, Indian 
Ayurveda, as well as Indonesian Jawa—is deeply rooted in Suriname [27, 28]. 
Furthermore, Suriname’s large biodiversity provides ample and readily available 
raw material that can be processed into ethnopharmacological plant-based prepara-
tions [29]. As a result, many diseases including cancer are often treated with such 
medications instead of, or in conjunction with, allopathic forms of treatment [30] 
despite the availability of affordable and accessible modern health care throughout 
the entire country.
This holds true for, for instance, patients who are motivated by aversion of 
“chemical” drugs with attendant adverse or side effects and those whose philosophy 
about life is not compatible with the use of allopathic medicine or who have reserva-
tions about the viewpoints of allopathic medicine [31]. Others prefer traditional 
treatments because these modalities would improve conventional therapies and 
represent gentler means of managing their disease when compared to allopathic 
medicines [32]. Still other patients, particularly those with advanced disease or can-
cer that, from a medical standpoint, can no longer be treated, resort to traditional 
medicines as an ultimate means to improve their situation [33]. And cultural beliefs, 
traditional values, and certain perceptions of health and disease may entice some 
people to choose for a familiar traditional therapy rather than a “western” therapy 
[34, 35].
4. Plants for treating cancer in Suriname
Hereunder, nine plants that are used in Suriname for treating cancer have in 
detail been assessed for their presumed activity against this disease. The plants have 
been selected after consulting a number of comprehensive publications describing 
various aspects of medicinal plants in the country [36–43]. Several of these plants 
such as the graviola Annona muricata L. (Annonaceae), Aloe vera (L.) Burm.f. 
(Asphodelaceae), the bitter melon Momordica charantia L. (Cucurbitaceae), the 
neem tree Azadirachta indica A.Juss., 1830 (Meliaceae), Moringa oleifera Lam. 
(Moringaceae), several subspecies and varieties of the black nightshade Solanum 
nigrum L. (Solanaceae), as well as the noni Morinda citrifolia L. (Rubiaceae) have 
elaborately been dealt with in the literature. This led us to decide to leave these plants 
out of the current chapter and address a number of less well-known plants, which 
prima facie may not qualify for evaluation for their anticancer potential (Table 1).
4.1 Annonaceae—Annona squamosa L.
The sugar apple A. squamosa (Figure 2) is probably native to the tropical parts 
of South America and the Caribbean but is now widely cultivated for its flavorful 
fruit in many other tropical and subtropical regions throughout the world. Unripe 
fruits as well as seeds and leaves contain toxic alkaloids with effective vermicidal 
and insecticidal properties [44]. For these reasons, the seed oil is commonly used to 
treat head lice [44]. A. squamosa preparations are also used against gastrointestinal 
ailments, urinary tract infections, irregular menstrual flow, and cancer [42, 43, 45]. 
The therapeutic efficacy of some of these applications may be attributed to aceto-
genins, terpenes and terpenoids, as well as alkaloids [45, 46].
The seed oil as well as the essential oils from the pericarp, the leaves, and the 
stembark of A. squamosa displayed anticancer activity against a broad range of 
human cancer cell lines [47–62] as well as H22 hepatoma implanted into laboratory 
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Figure 2. 
The sugar apple Annona squamosa L. (Annonaceae) (from: https://goo.gl/images/Lh5g7Z).
Family Species (vernacular 
names in English; 
Surinamese)
Part(s) 
used
Active constituent(s) References
Annonaceae Annona squamosa 
L. (sugar-apple; 
kaner’apra)
Oil from 
seed, 
pericarp, 
leaf, 
stembark
Annonaceous 
acetogenins, terpenes/
terpenoids, alkaloids
[47–67]
Asteraceae Cyanthillium 
cinereum (L.) H.Rob. 
(little ironweed; 
doifiwiwiri)
Whole plant Sesquiterpene lactones [74–79]
Asteraceae Eclipta prostrata 
(L.) L. (false daisy; 
luwisa wiwiri)
Leaf, aerial 
parts, whole 
plant
Terthiophenes/
thiophenes, saponins, 
triterpenoids, 
coumestans, flavonoids
[84–94]
Fabaceae Abrus precatorius 
L., 1753 (crab’s eye; 
kokriki)
Seed, leaf Abrin, phenolics, 
flavonoids
[100–110]
Fabaceae Tephrosia sinapou 
(Buch.) Chev. 
(Surinam poison; 
bumbi)
Root, leaf, 
aerial parts, 
stem
Benzil derivatives, 
coumestan derivatives, 
flavones/flavonoids, 
phenols
[118–131]
Loranthaceae Phthirusa stelis (L.) 
Kuijt (bird vine; 
pikin fowru doti)
Whole 
plant, stem, 
leaf
Peptides, alkynic fatty 
acids, lectins, triterpenes, 
glycosides, flavonoids
[135–148]
Rubiaceae Uncaria guianensis 
(Aubl.) J.F. Gmel. 
(cat’s claw; 
popokainangra)
Stembark Oxindole alkaloids [157–162]
Simaroubaceae Quassia amara 
L. (bitterwood; 
kwasibita)
Stem, leaf Quassinoids, canthin 
alkaloids
[171–178]
Zingiberaceae Zingiber officinale 
(ginger; gember, 
dyindya)
Rhizome Gingerols, shogaols [187–203]
Table 1. 
Plants with anticancer activity addressed in this chapter, parts preferentially used, presumed constituents with 
anticancer and chemoprotective activity, and references supporting these activities.
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mice [51, 60–63]. The anticancer effects have particularly been attributed to annona-
ceous acetogenins in the seed oil [47–53, 59] as well as annonaceous acetogenins, 
terpenes, and terpenoids, and alkaloids in pericarp, leaves, and stembark [56–58, 
60–62]. Interestingly, the acetogenin squamoxinone-D displayed selective cyto-
toxicity against the (drug-resistant) SMMC 7721/T cell line [59], and annonaceous 
acetogens were highly active in H22 hepatoma-bearing laboratory mice [64].
The antitumor activities have in some cases been associated with cycle arrest 
effects and apoptotic events [54, 60–62] as indicated by the increased caspase-3 
activity, the downregulation of antiapoptotic genes, and the fragmentation of the 
nuclear DNA [54, 60]. The mechanism underlying these events presumably involves 
the generation of oxidative stress [54]. This supposition is based on the enhanced 
generation of intracellular reactive oxygen species and the decreased levels of 
intracellular glutathione species noted in cultured human cells undergoing apopto-
sis following exposure to A. squamosa seed oil [54, 60].
Notably, leaf and stembark extracts protected Swiss albino mice and Syrian 
golden hamsters from the mutagenic effects of the alkylating agent cyclophospha-
mide [65] or the potent laboratory carcinogen 7, 12 dimethylbenz(a) anthracene 
(DMBA) [66], respectively. Furthermore, aqueous and ethanolic stembark extracts 
decreased lipid peroxidation and potentiated antioxidant activities in an animal 
model of oral carcinogenesis [67]. These observations suggest that A. squamosa also 
possesses chemopreventive properties.
4.2 Asteraceae—Cyanthillium cinereum (L.) H.Rob.
The little ironweed C. cinereum, also known as Vernonia cinerea (L.) Less. 
(Figure 3), is native to the tropical parts of Africa and Asia but has become natural-
ized in various other tropical regions including those in South America and the 
Caribbean. The plant is traditionally used for treating genitourinary disorders, 
gastrointestinal complaints, and respiratory ailments; to stimulate perspiration in 
malaria patients; against childhood conditions including bed-wetting; and to fight 
cancer [42, 43, 68]. C. cinereum seeds yield vernonia oil that contains vernolic acid 
[69], a natural epoxy fatty acid that may serve as a renewable starting material for 
manufacturing adhesives, paints, dyes, coatings, composites, and plastics [70].
Pharmacological and phytochemical studies have shown a wide range of bioac-
tive compounds such as (a) sesquiterpene lactone(s), which may lend credit to the 
traditional uses [68]. Two clinical trials found C. cinereum preparations efficacious 
in smoking cessation [71], while one study reported encouraging results with a 
Figure 3. 
The little ironweed Cyanthillium cinereum (L.) H.Rob. (Asteraceae) (from: https://goo.gl/images/Lh5g7Z).
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Figure 4. 
The false daisy Eclipta prostrata (L.) (Asteraceae) (from: https://goo.gl/images/YGw37Z).
herbal C. cinereum-containing preparation in patients with type 2 diabetes mellitus 
[72]. However, the clinical evidence available at this moment is insufficiently sound 
to support these applications [73].
Support for anticancer activity of C. cinereum came from the potent cytotoxicity 
of an extract from the whole plant against various drug-sensitive and multidrug-
resistant human tumor cell lines [74–76]. The whole-plant extract caused the cells to 
apoptose and sensitized them to common cytotoxic drugs [76]. Furthermore, such 
an extract as well as the sesquiterpene lactone vernolide A stimulated the activity of 
cytotoxic T lymphocytes and natural killer cells and enhanced antibody-dependent 
cellular cytotoxicity and antibody-dependent complement-mediated cytotoxic-
ity in tumor-bearing BALB/c mice by increasing the secretion of interleukin-2 
and interferon-γ [77]. This suggests that (this) sesquiterpene lactone may play an 
important role in the anticancer activity of C. cinereum [68, 78].
Other indications for anticancer activity of C. cinereum preparations were the 
inhibitory effects of a 70%-methanol whole-plant extract on the in vitro prolifera-
tion, invasion, migration, and matrix metalloproteinase activation of B16F-10 
murine melanoma cells [79]. The extract also prevented the formation of lung 
metastases by the B16F-10 cells in C57BL/6 mice, lowered vascular-endothelial 
growth factor (VEGF) levels in the animals, and substantially increased their life 
span when compared to untreated controls [79]. Together, these observations raise 
the possibility that C. cinereum may exert its anticancer activity by boosting the 
immune system, suppressing angiogenesis, and inhibiting drug transport mecha-
nisms in addition to direct cytotoxicity.
4.3 Asteraceae—Eclipta prostrata (L.) L.
The false daisy E. prostrata, also known as E. alba (L.) Hassk. or E. erecta L. 
(Figure 4), is probably native to either Asia or the Americas but is now commonly 
encountered in subtropical and tropical regions throughout the world. It has 
become an invasive weed in many parts of the tropics, which is particularly due 
to its ability to grow fast and flower early. The tender leaves and young shoots are 
consumed as a vegetable but may also serve as a source for the synthesis of titanium 
dioxide nanoparticles (nano-TiO2) [80]. Nano-TiO2 is widely employed to provide 
whiteness and opacity to paints, plastics, papers, inks, food colorants, and tooth-
pastes; for the production of cosmetics and skin care products such as sun blocks 
because of its ability to protect the skin from UV rays while remaining transparent 
on the skin; and as an additive in antifogging coatings and self-cleaning windows 
because of its photocatalytic sterilizing properties [81].
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E. prostrata is an important herb in Indian traditional medicine and is used 
for treating a host of conditions such as skin wounds and certain skin disorders; 
toothache; hair loss and graying hair; gastrointestinal complaints; uterine disorders; 
microbial infections; as well as cancer [42, 43, 82]. Some of these claims may be 
attributable to the presence in the plant of various bioactive constituents including 
coumestans, thiophene derivatives, terthiophenes, flavonoids, as well as triterpe-
noids and their glycosides such as eclalbasaponins [82, 83].
Converging lines of evidence suggest that E. prostrata preparations and 
some of their constituents may elicit anticancer activity through multiple 
mechanisms including direct cytotoxicity, angiosuppression, and chemopre-
vention. The former possibility is supported by the growth inhibitory effects 
of crude extracts of the plant in a variety of drug-sensitive and drug-resistant 
cell lines [84–87] while causing apoptosis in some cases [87, 88]. Also, an orally 
administered methanolic leaf extract exerted encouraging anticancer activity 
against Ehrlich ascites carcinoma in Swiss albino mice [89], and a hydroalco-
holic extract reversed multidrug resistance in an animal model of liver cancer 
induced by diethylnitrosamine and 2-acetylaminofluorene [86]. Furthermore, 
terthiophenes, thiophenes, saponins, triterpenoids, coumestans, and flavonoids 
isolated from the aerial parts exhibited cytotoxicity against cultured SKOV3 
human ovarian cancer cells [90]; an eclalbasaponin I-containing fraction from 
the aerial parts and the saponin dasyscyphin-C isolated from the leaves inhib-
ited the in vitro proliferation of SMMC-7721 human hepatocarcinoma and HeLa 
human cervical carcinoma cells, respectively [85, 91]; and eclalbasaponin II 
induced cytotoxicity as well as apoptotic and autophagic cell death in human 
ovarian cancer cell lines [92].
That E. prostrata may also exhibit angiosuppressive activities can be derived 
from the inhibitory effect of the juice from the whole plant on invasion, migration, 
and adhesion of a variety of cancer cell types and endothelial cells in the chick cho-
rioallantoic membrane assay [93]. And indications for chemopreventive actions of 
this plant were provided by the growth inhibitory effect of a coumastan-containing 
methanolic whole-plant extract in an experimental skin cancer in mice [94]. This  
presumably occurred by restoring endogenous antioxidant defense mechanisms, 
enhancing immunosurveillance, silencing cell cycle progression signals, and induc-
ing stable expression of p53 [94].
4.4 Fabaceae—Abrus precatorius L., 1753
The crab’s eye or rosary pea A. precatorius (Figure 5) is a slender, woody, 
climbing plant that grows twisting around trees, shrubs, and hedges and probably 
originates from India. However, due to its severely invasive capacity, this plant is 
now commonly encountered in many tropical and subtropical parts of the world. 
Its deep roots are very difficult to remove, and its aggressive growth, hard-shelled 
seeds, and ability to sucker make it very difficult to eradicate and to prevent re-
infestation. The brightly red colored seeds are used to make necklaces and other 
ornaments as well as percussion instruments in various cultures. However, they are 
very toxic because of their high content of the toxalbumin abrin, and ingestion of a 
single well-chewed seed can be fatal [95].
The sweet-tasting leaves of the plant are used in West Tropical Africa to 
sweeten foods [96]. These parts of the plant along with the seeds (after denatur-
ing abrin at high temperatures [97]) are also used in various traditional medicinal 
systems for treating or preventing tetanus, inflammation, snake bites, rabies, and 
leukoderma; as aphrodisiacs; as oral contraceptives and abortifacients; and for 
treating cancer [42, 98].
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Pharmacological studies with preparations from A. precatorius seeds and leaves 
revealed that many of their biological activities may be attributable to abrin [98]. 
This compound consists of a dimer with a B subunit that facilitates its entry into 
cells by binding to plasma membrane-associated transport proteins, after which the 
A subunit inactivates the 26S subunit of ribosomes, preventing protein synthesis 
[99]. One molecule of abrin is able to inactivate up to 1500 ribosomes per second 
[95], indicating its powerful inhibitory effect on protein synthesis. On the other 
hand, this mechanistic feature of abrin presents the opportunity of inhibiting the 
proliferation of cancerous cells which characteristically have a higher metabolic 
turnover when compared to normal cells.
Indeed, protein-rich extracts or peptide fractions from A. precatorius seeds 
and ethanol, ethyl acetate, and water extracts from the leaves potently inhibited 
the proliferation of several tumor cell lines [100–104] without affecting the 
growth of normal murine peritoneal macrophages [102]. The cytotoxic effects 
were accompanied by upregulation of particularly p21 and p53 levels [104] and 
clear signs of apoptosis occurring through the mitochondrial pathway [101]. The 
seed preparations also inhibited the growth of several tumor types implanted into 
laboratory rodents [105–108]. And direct injection of abrin into a murine Meth-A 
sarcoma growing in syngeneic BALB/c mice led to regression of the tumor [109]. 
The anticancer effects might be related to the antioxidant activities of phenolics and 
flavonoids in the extracts [102, 104].
Importantly, administration of Meth-A tumor cells which had been treated 
in vitro with abrin, induced strong antitumor immunity of the mice [109]. This 
suggests that the antitumor effects of abrin were also produced by boosting the 
immune system. Support for this presumption came from the immunopotentiating 
and immunostimulatory properties of abrin [107, 110] and the behavior of Abrus 
agglutinin as a B cell and T cell stimulator [111].
4.5 Fabaceae—Tephrosia sinapou (Bucholz) A.Chev.
The Surinam poison T. sinapou, also known as T. toxicaria (Swartz) Pers. 
(Figure 6), is native to parts of Central America, the Caribbean, and tropical 
South America. The plant is mainly known for its high content of the isoflavonoids 
rotenone and tephrosin in its black roots and seeds, which are used as a fish poison 
by the Amazon Indigenous peoples [112, 113]. Particularly rotenone is also highly 
toxic to insects and pests [112, 113]. For this reason, Guyana hinterland peoples use 
the root sap or the leaf juice externally against head lice [112]. These preparations 
are also used to ward off evil spirits and for treating eczema, snakebites, syphilis, 
Figure 5. 
The crab’s eye Abrus precatorius L., 1753 (Fabaceae) (from: https://goo.gl/images/8VobSd).
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and gonorrhea, as well as skin ulcers associated with AIDS and cancer [42, 43, 114]. 
These health benefits have particularly been ascribed to the rotenoids and other 
flavonoids in roots, leaves, and aerial parts of the plant [115–117].
Indications for anticancer activity of Tephrosia preparations were provided by 
the cytotoxic effects of extracts from parts of T. calophylla Bedd., T. persica Boiss., 
T. purpurea (L.) Pers., T. villosa (L.) Pers., and T. vogelii Hook F. against human 
carcinoma cell lines and brine shrimp cultures [118–124]. In some cases, the cyto-
toxic effects were accompanied by signs of apoptotic cell death [118]. Comparable 
anticancer effects were produced by benzil and coumestan derivatives from a T. 
calophylla root extract [125]; flavonoids from parts of T. calophylla, T. pulcherrima 
(Baker) Gamble, and T. pumila (Lam.) Pers. [126]; phenol- and flavonoid-rich 
methanolic extracts from the leaves of T. purpurea and the aerial parts of T. apollinea 
(Delile) DC. [124, 127]; and a prenylated flavone from the aerial parts of T. apollinea 
[128]. Notably, the high flavonoid content of the aerial parts of T. apollinea has also 
been associated with potent anti-angiogenic activity in an ex vivo rat aortic ring 
assay [127].
There are also indications for cancer chemopreventive activity of Tephrosia 
preparations. Thus, flavonoids from an ethyl acetate-soluble extract of T. sinapou 
stem selected for potential cancer chemopreventive properties in an in vitro assay 
for quinone reductase induction, inhibited the formation of preneoplastic lesions 
induced by DMBA in a mouse mammary organ culture [129]. Furthermore,  
T. purpurea extracts substantially reduced the formation of skin lesions in Swiss 
albino mice treated with the potent tumor promoter phorbol 12-myristate 13-ace-
tate (PMA) following treatment with DMBA [130]. The extract also inhibited the 
development of hepatocellular carcinoma in Wistar rats treated with the carcino-
genic and mutagenic compound N-nitrosodiethylamine [131].
4.6 Loranthaceae—Phthirusa stelis (L.) Kuijt
The bird vine P. stelis (Figure 7) is, like many of its relatives in the plant family 
Loranthaceae (commonly known as mistletoes), a small flowering plant that grows 
Figure 6. 
The Suriname poison Tephrosia sinapou (Bucholz) A.Chev. (Fabaceae) (from: https://goo.gl/images/q6BZZN).
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hemiparasitically on the branches of trees and shrubs. It is encountered in various 
Southern and Middle American countries between Costa Rica and Bolivia where it 
often constitutes a serious pest on cultivated trees of economic importance such as 
rubber, orange, cocoa, and bread fruit trees [132]. P. stelis is mostly spread by bird 
droppings, hence the abovementioned Surinamese vernacular name of “pikin fowru 
doti” meaning small birds’ excrement.
None of the parts of the plant have edible uses. However, the viscous layer of its 
fruits has been suggested to represent a potential source of natural rubber [133]. P. stelis 
preparations are traditionally used to treat oral candidiasis in children; leukorrhea; 
problems of the female reproductive system; tonsillitis; and skin problems such as sca-
bies [42, 43, 134]. The plant is also used as a chemopreventive substance and by cancer 
patients for whom no other options are available, presumably because of its hemipara-
sitic, cancer-like lifestyle, which would signal its usefulness for these purposes [43].
Indications for anticancer activity of P. stelis are scant, being limited to the 
cytotoxic effects of small polypeptides of 3–5 kDa isolated from dried dichloro-
methane or ethanol whole-plant extracts in cultured U-937 GTB human histiocytic 
lymphoma cells [135]. This finding is in line with the identification of (larger) 
cytotoxic peptides in the Loranthaceae species Helicanthus elastica (Desr.) Dans. 
[136] and Ligaria cuneifolia (Ruiz & Pav.) van Tiegh. [137]. Other phytochemicals 
in Loranthaceae species with in vitro anticancer activity are alkynic fatty acids in 
Scurrula atropurpurea (BL.) Dans. [138]; lectins in Viscum album coloratum Kom. 
[139]; the triterpene moronic acid in Phoradendron reichenbachianum (Seem.) Oliv. 
[140]; glycosides in Macrosolen globosus (Roxb.) Tiegh. [141], Loranthus tanakae 
Franch. & Sav. (Loranthaceae) [142], and Viscum coloratum (Kom.) Nakai [143]; 
and flavonoids in L. cuneifolia [144].
Crude extracts from stem or leaves of Scurrula oortiana (Korth.) Danser [145], 
leaves of Dendrophthoe pentandra (L.) Miq. [146], and stem of Elytranthe parasitica (L.) 
Danser [147] also exerted cytotoxic effects. In addition, the alkynic fatty acids from  
S. atropurpurea potently inhibited in vitro tumor cell invasion [148], and extracts from 
the stem or leaves of S. oortiana increased tumor cell sensitivity to TNF-α-mediated 
lysis [145].
Figure 7. 
The bird vine Phthirusa stelis (L.) Kuijt (Loranthaceae) (from: https://goo.gl/images/J9D1zG).
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4.7 Rubiaceae—Uncaria guianensis (Aubl.) J.F. Gmel.
The cat’s claw U. guianensis (Figure 8) is indigenous to the Amazonian parts of 
Paraguay, Brazil, Bolivia, Peru, Ecuador, Colombia, Venezuela, and the Guyanas. 
Preparations from its stembark and leaves have a long history of traditional medici-
nal use and are particularly employed for treating osteoarthritis and rheumatoid 
arthritis [42, 43, 149]. Pharmacological studies with extracts from U. guianensis—
and with those from other closely related species, mainly U. tomentosum (Willd. ex 
Schult.) DC—indeed showed anti-inflammatory activities [150]. These effects have 
primarily been attributed to pentacyclic oxindole alkaloids [149–152]. Clinical stud-
ies with an U. guianensis stembark extract or a highly purified pentacyclic oxindole 
alkaloids fraction from U. tomentosum reported some benefits in patients with 
osteoarthritis of the knee [153–155]. However, the overall clinical data are insuf-
ficient to draw a firm conclusion about the anti-inflammatory efficacy of Uncaria 
preparations [156].
No studies have been carried out on the anticancer activity of U. guianensis. 
However, studies with the oxindole alkaloids from U. tomentosa stembark showed 
notable anticancer activity against human cancer cell lines [157–160] and a mouse 
model [159] which was in some cases accompanied by apoptosis [157]. In addi-
tion, Uncaria preparations may possess immunomodulatory and chemopreventive 
properties besides direct cytotoxic activity. The former assumption is supported 
by the involvement of anti-inflammatory processes rather than cytotoxic events in 
the antitumor activity of a hydroethanolic U. guianensis stembark extract in 4 T1 
mammary tumor-bearing BALB/c mice [161]. The latter supposition stems from the 
changes in expression patterns of critical proto-oncogenes and tumor suppressor 
genes in DMBA-treated CBA/Ca mice following administration of Claw of Dragon 
tea (CoD™ tea), a mixture of the stembarks from U. guianensis, U. tomentosa, and 
the trumpet-tree Tabebuia avellanedae Lorentz ex Griseb. (Bignoniaceae) [162].
A clinical trial with a dried extract of U. tomentosa stembark reported improved 
overall quality of life, social functioning, and fatigue in patients with advanced 
solid tumors, but there were no improvements in biochemical and inflammatory 
markers or tumor responses [163]. Another trial found a decrease in the occur-
rence of neutropenia caused by the 5-fluorouracil-doxorubicin-cyclophosphamide 
combination in patients with breast cancer [164]. However, a third study found 
no effect of oral tablets containing a dried ethanolic U. tomentosa stembark on the 
most prevalent adverse events caused by the 5-fluorouracil-oxaliplatin regimen in 
colorectal cancer patients [165].
Figure 8. 
The cat’s claw Uncaria guianensis (Aubl.) J.F. Gmel. (Rubiaceae) (from: https://goo.gl/images/7ezTTN).
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4.8 Simaroubaceae—Quassia amara L.
The bitterwood Q. amara (Figure 9) is native to South and Central America but 
is now also cultivated in various other tropical and subtropical regions throughout 
the world. In Suriname, the plant has been named “kwasibita” (Kwasi’s bitter) after 
the freedman Kwasi or Quassi (1692–1787) who was the first to broadly apply the 
remarkable medicinal properties of the hardwood for treating malaria fevers [28]. 
The plant contains triterpene quassinoids, secondary metabolites that are among 
the bitterest in nature [166]. These compounds are almost exclusively encountered 
in members of the Simaroubaceae and are a taxonomic marker of this plant family 
[166]. They constitute basic ingredients of Angostura bitters, concentrated alco-
holic preparations produced by the House of Angostura in Trinidad and Tobago, 
which are key ingredients of cocktails such as gin-based drinks.
The quassinoids quassin, neoquassin, bruceantin, and simalikalactones D and 
E have been associated with a host of pharmacological activities including antima-
larial, insecticidal, anti-inflammatory, antimicrobial, and antianorectic activities 
[166–168]. Other Q. amara phytochemicals with a broad pharmacological spectrum 
are canthin-6-one alkaloids, which displayed antiviral, antiparasitic, antibacterial, 
anti-inflammatory, and cytotoxic activities [166, 168, 169]. Notably, a 4%-Quassia 
cream containing both groups of phytochemicals has been found safe and effective 
in the management of rosacea [170].
There is ample evidence that Q. amara preparations and some of its constitu-
ents also possess anticancer activity. For instance, crude stem or leaf extracts, 
quassimarin- and/or similikalactone-enriched fractions, partially purified quas-
sinoid-containing fractions, as well as quassimarin, similikalactones, and canthin 
alkaloids displayed substantial cytotoxicity against human carcinoma cell lines 
[171–174] as well as P-388 lymphocytic leukemia inoculated into laboratory mice 
[171]. Importantly, the quassinoids did not affect the viability of nontumorogenic 
African green monkey Vero kidney cells [173] and produced anticancer effects 
at lower concentrations than those required for antimalarial effects [172, 173]. 
Comparable results were found with quassinoids and/or canthin alkaloids from 
other members of the Simaroubaceae family [175–178]. Markedly, the quassinoids 
and canthin alkaloids also prevented the activation of Epstein-Barr virus early 
antigen by PMA [175] and inhibited the activity of CYP1A1, a cytochrome P450 
isoform with presumed carcinogen-activating properties [179]. These observations 
suggest that these compounds may also possess chemopreventive properties.
Based on this large body of preclinical data, several Q. amara constituents have 
undergone clinical evaluation in patients with advanced solid and hematological 
Figure 9. 
The bitterwood Quassia amara L. (Simaroubaceae) (from: https://goo.gl/images/d5ZqEd).
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malignancies. Unfortunately, the results from phase 1 and phase 2 studies with 
bruceantin—as well as Fructus bruceae oil obtained from the dried ripe fruits of 
Brucea javanica (L.) Merr.—were uniformly disappointing, showing no meaningful 
anticancer activity but substantial toxicity [180–182].
4.9 Zingiberaceae—Zingiber officinale Roscoe
The ginger Z. officinale (Figure 10) is presumably native to the Indian subcontinent 
and other Southern Asian regions. This plant was probably introduced in Suriname by 
Javanese indentured laborers around the beginning of the twentieth century [28, 38]. 
The rhizome is extensively used as a hot and fragrant kitchen spice in many cuisines 
and to prepare various hot and cold beverages. This part of the plant also has many 
long-standing traditional uses [43, 183]. The essential oil from the rhizomes is topically 
applied as an analgesic, while preparations from powdered fresh or dried rhizomes are 
orally or topically used for treating, among others, respiratory complaints; obesity; 
microbial infections; vertigo, travel sickness, morning sickness, as well as nausea and 
vomiting associated with surgery and chemotherapy; and cancer [43, 183].
These claims are supported by the pharmacological activities displayed by par-
ticularly gingerols (such as zingerone and zingeberol) and shogaols in the rhizomes. 
Gingerols are the main compounds in the volatile oil of fresh ginger rhizomes and 
are responsible for their characteristic fragrance [184]. They are thermally labile 
and easily undergo dehydration reactions to form the corresponding shogaols, 
which convey the typical pungent taste of dried ginger during cooking [184]. Both 
gingerols and shogaols exhibited pharmacological activities which supported the 
traditional uses of Z. officinale [185, 186].
A host of data supports that gingerols and shogaols possess both anticancer 
and chemopreventive activities. Evidence for the former suggestion came from 
their inhibitory effects on the proliferation, cell cycle progression, and viability of 
human carcinoma cell lines [187–197] and tumors implanted into laboratory animal 
[198, 199]. Suggestions for chemopreventive activities of these compounds came 
from their inhibitory effects on the development of cancer in animals treated with 
laboratory carcinogens [199–203]. Both activities may be mediated by multiple 
mechanisms including inhibition of invasion through activation of the nuclear 
receptor peroxisome proliferator-activated receptor γ (PPAR-γ) [197]; downregu-
lation of matrix metalloproteinase 9 transcription [204]; suppression of tumor 
angiogenesis [191, 194]; deactivation of aberrant cell cycle-regulating elements 
[189, 200]; and interference with microtubule integrity [190, 196].
Figure 10. 
The ginger Zingiber officinale Roscoe (Zingiberaceae) (from: https://goo.gl/images/Tr2fgV).
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All these observations have led to the consideration of Z. officinale preparations 
for treating cancer as well as cancer-related complications such as chemotherapy-
induced nausea and vomiting. So far, however, there is no scientific proof of clinical 
efficacy against either cancer [205] or nausea and vomiting resulting from chemo-
therapy or surgery [206].
5. Concluding remarks
The nine plants addressed in this chapter have a long traditional use in Suriname 
against various conditions including neoplastic disease and indeed showed some 
evidence of anticancer activity. However, in all cases, the evidence was limited 
to preclinical models and was not sufficient to support claims of clinical efficacy. 
However, this does not necessarily mean that these plants and their active constitu-
ents should be discarded as failed compounds. Some may constitute useful parts of 
an integrative medical approach for treating or preventing cancer. Others—includ-
ing many mentioned in this chapter—may boost the immune system or improve 
overall health, well-being, and quality of life. And still others may help relieve some 
of the symptoms of cancer such as fatigue or reduce the side effects of chemo-
therapy and radiotherapy.
Converging lines of evidence lend support to these suppositions. Firstly, sev-
eral phenolic compounds such as curcumin from the turmeric Curcuma longa L. 
(Zingiberaceae) and apigenin from the celery Apium graveolens L. (Apiaceae) may 
directly or indirectly exert cytotoxic and apoptotic effects by stimulating autophagy 
[207, 208]. Other plant phenols such as luteolin in celery, thyme, green peppers, and 
chamomile tea; epigallocatechin-3-gallate in Chinese green tea; and resveratrol in the 
skin of grapes, blueberries, raspberries, and mulberries have shown promise in the 
treatment and prevention of cancer [209–211]. These compounds are able to inacti-
vate molecular signals and transcription pathways essential for cancer cells, scavenge 
harmful free radicals, and inhibit tumor angiogenesis, respectively [209–211].
Secondly, mistletoe extracts may alleviate cancer-related fatigue [212]; 
preparations from the holy basil Ocimum sanctum L. (Lamiaceae) may avert 
radiation-induced clastogenesis [213]; those based on A. vera may prevent or treat 
radiation-induced oral mucositis [214]; and the gingerols and shogaols in  
Z. officinale may reduce the cardiotoxicity of doxorubicin [215]. These compounds 
may exercise their protective effects through their anti-inflammatory, immune-
modulating, free radical-scavenging, antioxidant, and/or metal-chelating proper-
ties [212–215].
Furthermore, recent advances in analytical and computational techniques as 
well as the introduction of innovative technologies such as predictive computational 
software may help employ apparently “useless” anticancer compounds in novel 
ways. For instance, the rejected tubulin-binding maytansines from Maytenus species 
(Celastraceae) may have found a new use as “warheads” attached to specific antitu-
mor monoclonal antibodies in order to precisely attack tumor tissues while causing 
little toxicity [216]. And the discarded topoisomerase I inhibitor lapachol from the 
stembark of the Surinam greenheart Handroanthus serratifolius (Vahl) S.O. Grose—
also known as Tabebuia serratifolia (Vahl) G. Nicholson (Bignoniaceae)—is attract-
ing renewed attention following reports that its inhibitory effect on melanoma cell 
proliferation may involve interference with glycolysis and decreasing ATP levels [217].
Likewise, the therapeutic index of gingerols in the treatment of breast cancer 
may improve when formulated as a PEGylated nanoliposomal form, allowing for 
high specificity, improved bioavailability, slow release, and low systemic toxicity 
[218]. And structural modifications of quassinoids on the basis of, for instance, 
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(quantitative) structure-activity relationships, may produce more potent and less 
toxic analogues [219, 220]. These and many other examples support continued 
assessment of the plants and their bioactive compounds dealt with in the cur-
rent chapter for their usefulness against cancer. If only one of these compounds 
would reach the clinic, the efforts invested in their evaluation would have been 
worthwhile.
Conflict of interest
The authors declare that no conflict of interest exists.
Author details
Dennis R.A. Mans1* and Euridice R. Irving2
1 Department of Pharmacology, Faculty of Medical Sciences, Anton de Kom 
University of Suriname, Paramaribo, Suriname
2 Department of Medical Skills Education, Faculty of Medical Sciences, Anton de 
Kom University of Suriname, Paramaribo, Suriname
*Address all correspondence to: dennismans16@gmail.com
20
Pharmacognosy - Medicinal Plants
References
[1] Idikio HA. Human cancer 
classification: A systems biology-based 
model integrating morphology, cancer 
stem cells, proteomics, and genomics. 
Journal of Cancer. 2011;2:107-115
[2] Yadav M, Chatterjee P, Tolani S, 
Kulkarni J, Mulye M, Chauhan N, et al. 
A Nexus model of cellular transition in 
cancer. Biological Research.  
2018;51:23. DOI: 10.1186/
s40659-018-0173-8
[3] Bray F, Ferlay J, Soerjomataram I, 
Siegel RL, Torre LA, Jemal A. Global 
cancer statistics 2018: GLOBOCAN 
estimates of incidence and mortality 
worldwide for 36 cancers in 185 
countries. CA: A Cancer Journal for 
Clinicians. 2018;0:1-31
[4] Shield KD, Ferlay J, Jemal A, 
Sankaranarayanan R, Chaturvedi AK, 
Bray F, et al. The global incidence of lip, 
oral cavity, and pharyngeal cancers by 
subsite in 2012. CA: A Cancer Journal 
for Clinicians. 2017;67:51-64
[5] Catarino R, Petignat P, Dongui G, 
Vassilakos P. Cervical cancer screening 
in developing countries at a crossroad: 
Emerging technologies and policy 
choices. World Journal of Clinical 
Oncology. 2015;6:281-290
[6] Akulapalli Sudhakar A. History 
of cancer, ancient and modern 
treatment methods. Journal of Cancer 
Science and Therapy. 2009;1:i-iv. DOI: 
10.4172/1948-5956.100000e2
[7] Cragg GM, Newman DJ. Natural 
products: A continuing source of novel 
drug leads. Biochimica et Biophysica 
Acta. 2013;1830:3670-3695
[8] Mans DRA. From forest to pharmacy: 
Plant-based traditional medicines 
as sources for novel therapeutics. 
Academia Journal of Medicinal Plants. 
2013;1:101-110
[9] Newman DJ, Cragg GM. Natural 
products as sources of new drugs 
from 1981 to 2014. Journal of Natural 
Products. 2016;79:629-661
[10] Iqbal J, Abbasi BA, Mahmood T,  
Kanwal S, Ali B, Shah SA, et al. 
Plant-derived anticancer agents: A 
green anticancer approach. Asian 
Pacific Journal of Tropical Biomedicine. 
2017;7:1129-1150
[11] Van Der Heijden R, Jacobs DI, 
Snoeijer W, Hallard D, Verpoorte R. The 
Catharanthus alkaloids: Pharmacognosy 
and biotechnology. Current Medicinal 
Chemistry. 2004;11:607-628
[12] Kingston DG, Newman DJ. Taxoids: 
Cancer-fighting compounds 
from nature. Current Opinion in 
Drug Discovery & Development. 
2007;10:130-144
[13] Legarza K, Yang LX. Novel 
camptothecin derivatives. In Vivo. 
2005;19:283-292
[14] Baldwin EL, Osheroff N. Etoposide, 
topoisomerase II and cancer. Current 
Medicinal Chemistry. Anti-Cancer 
Agents. 2005;5:363-372
[15] Cragg GM, Newman DJ, Weiss RB. 
Coral reefs, forests, and thermal vents: 
The worldwide exploration of nature 
for novel antitumor agents. Seminars in 
Oncology. 1997;24:156-163
[16] Algemeen Bureau voor de Statistiek/
Censuskantoor. Suriname in cijfers 
2013/05. Resultaten achtste (8ste) volks- 
en woningtelling in Suriname (volume 
1) (General Bureau of Statistics/Census 
The Office Suriname in numbers 
2013/05. Results of the Eight General 
Census of Suriname). Demografische 
en sociale karakteristieken en migratie 
(Demographic and social characteristics 
and migration). Paramaribo: Algemeen 
Bureau voor de Statistiek; 2013
21
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
[17] Oehlers GP, Lichtveld MY, Brewster 
LM, Algoe M, Irving ER. Health life in 
Suriname (chapter 6). In: Hassankhan 
MS, Roopnarine L, White C, Mahase 
R, editors. Legacy of Slavery and 
Indentured Labour. Historical and 
Contemporary Issues in Suriname and 
the Caribbean. New Delhi: Manohar; 
2016. pp. 111-150
[18] Eersel MGM, Vreden SGS, van Eer 
ED, Mans DRA. Fifty years of primary 
health care in the rainforest: Temporal 
trends in morbidity and mortality in 
indigenous Amerindian populations 
of Suriname. Journal of Global 
Health. 2018;8:020423. DOI: 10.7189/
jogh.08.020403
[19] Algemeen Bureau voor de 
Statistiek. Suriname in cijfers 303-
2014-04 (General Bureau of Statistics 
Suriname in Numbers 303-2014-04). 
Basis Indicatoren (Basic Indicators). 
Paramaribo: Algemeen Bureau voor de 
Statistiek; 2014
[20] The World Bank Group. Suriname 
[Internet]. 2018. Available from: https://
data.worldbank.org/country/suriname 
[Accessed: 10-03-2018]
[21] Ministry of Health. Report of 
the Director of Health 2005-2007. 
Paramaribo: Ministry of Health 
Republic of Suriname; 2008
[22] Dams E. Suriname National Cancer 
Control Plan 2018-2028. Prepared for 
the Ministry of Health. Paramaribo: 
Ministry of Health Republic of 
Suriname; 2017
[23] Mans DRA, Mohamedradja RN, 
Hoeblal AR, Rampadarath R, Joe 
SS, Wong J, et al. Cancer incidence 
in Suriname from 1980 through 
2000 a descriptive study. Tumori. 
2003;89:368-376
[24] Lamur HE. The demographic 
evolution of Surinam, 1920-1970. A 
sociodemographic analysis (chapter III). 
In: Lamur HE, editor. Verhandelingen 
van het Koninklijk Instituut voor Taal-, 
Land- en Volkenkunde 65 (Discourses of 
the Royal institute for Linguistics, Land 
Science, and Ethnology 65). The Hague: 
Martinus Nijhoff; 1973. pp. 96-98
[25] Punwasi W. Causes of death in 
Suriname 2010-2011. Bureau Openbare 
Gezondheidsdienst (Bureau of Public 
Health). Paramaribo: Ministry of Health 
Republic of Suriname; 2012
[26] ER I, DRA M. Age and ethnic 
differences in the occurrence of 
cervical dysplasia, cervical cancer and 
cervical cancer deaths in Suriname. 
Translational Biomedicine. 2015;6:1. 
DOI: 10.21767/2172-0479.100001
[27] Mans DRA. “Nature, green in leaf 
and stem”. Research on plants with 
medicinal properties in Suriname. 
Clinical and Medical Investigations. 
2016;2:1-10
[28] Mans DRA, Ganga D, Kartopawiro J.  
Meeting of the minds: Traditional herbal 
medicine in multiethnic Suriname 
(chapter 6). In: El-Shemy H, editor. 
Aromatic and Medicinal Plants—Back to 
Nature. Rijeka: InTech; 2017. pp. 111-132. 
DOI: 10.5772/66509.
[29] Hammond DS. Forest conservation 
and management in the Guiana shield 
(chapter 1). In: Hammond DS, editor. 
Tropical Rainforests of the Guiana 
Shield. Wallingford: CABI Publishing; 
2005. pp. 1-14
[30] Yue Q, Gao G, Zou G, Yu H, Zheng 
X. Natural products as adjunctive  
treatment for pancreatic cancer: 
Recent trends and advancements. 
BioMed Research International. 
2017;2017:8412508. DOI: 
10.1155/2017/8412508
[31] Marinac JS, Buchinger CL, Godfrey 
LA, Wooten JM, Sun C, Willsie SK.  
Herbal products and dietary 
supplements: A survey of use, attitudes, 
Pharmacognosy - Medicinal Plants
22
and knowledge among older adults. The 
Journal of the American Osteopathic 
Association. 2007;107:13-23
[32] Sparber A, Bauer L, Curt G, 
Eisenberg D, Levin T, Parks S, et al. 
Use of complementary medicine by 
adult patients participating in cancer 
clinical trials. Oncology Nursing Forum. 
2000;27:623-630
[33] Mansky PJ, Wallerstedt DB. 
Complementary medicine in  
palliative care and cancer symptom 
management. Cancer Journal. 
2006;1:425-431
[34] Daher M. Cultural beliefs and values 
in cancer patients. Annals of Oncology. 
2012;23(Suppl 3):66-69
[35] Luo T, Spolverato G, Johnston F, 
Haider AH, Pawlik TM. Factors that 
determine cancer treatment choice 
among minority groups.  
Journal of Oncology Practice/
American Society of Clinical Oncology. 
2015;11:259-261
[36] Stephen HJM. Geneeskruiden 
van Suriname: Hun toepassing in de 
volksgeneeskunde en in de magie 
(Herbal Medicines from Suriname: 
Their Applications in Folk Medicine and 
Wizardry). Amsterdam: De Driehoek; 
1979
[37] Heyde H. Surinaamse 
medicijnplanten (Surinamese Medicinal 
Plants). 2nd ed. Paramaribo: Westfort; 
1987
[38] Tjong Ayong G. Het gebruik van 
medicinale planten door de Javaanse 
bevolkingsgroep in Suriname (The Use 
of Medicinal Plants by the Javanese in 
Suriname). Paramaribo: Instituut voor 
de Opleiding van Leraren; 1989
[39] Slagveer JL. Surinaams Groot 
Kruidenboek: Sranan Oso Dresie 
(Surinamese Herbal Medicines). 
Paramaribo: De West; 1990
[40] Sedoc NO. Afrosurinaamse 
natuurgeneeswijzen: Bevattende meer 
dan tweehonderd meest gebruikelijke 
geneeskrachtige kruiden (Afro-
Surinamese Natural Remedies: Over 
Two Hundred Commonly Used 
Medicinal Herbs). Paramaribo: Vaco 
Press; 1992
[41] Raghoenandan UPD. Etnobotanisch 
onderzoek bij de Hindoestaanse 
bevolkingsgroep in Suriname (An 
ethnobotanical investigation among 
hindustanis in Suriname) [thesis]. 
Paramaribo: Anton de Kom University 
of Suriname; 1994
[42] DeFilipps RA, Maina SL, Crepin J.  
Medicinal Plants of the Guianas 
(Guyana, Surinam, French Guiana). 
Washington, DC: Smithsonian 
Institution; 2004
[43] Van Andel TR, Ruysschaert S. 
Medicinale en rituele planten van 
Suriname (Medicinal and Ritual 
Plants of Suriname). Amsterdam: KIT 
Publishers; 2011
[44] Zahid M, Mujahid M, Singh PK, 
Farooqui S, Singh K, Parveen S, et al. 
Annona squamosa Linn. (custard apple): 
An aromatic medicinal plant fruit with 
immense nutraceutical and therapeutic 
potentials. International Journal of 
Pharmaceutical Sciences and Research. 
2018;9:1745-1759
[45] Saha R. Pharmacognosy and 
pharmacology of Annona squamosa: 
A review. International Journal 
of Pharmacy and Life Sciences. 
2011;2:1183-1189
[46] Oo WM, Khine MM. 
Pharmacological activities of 
Annona squamosa: Updated 
review. International Journal 
of Pharmaceutical Chemistry. 
2017;3:86-93
[47] Xie H, Wei J, Liu M, Yang R. A new 
cytotoxic acetogenin from the seeds of 
23
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
Annona squamosa. Chinese Chemical 
Letters. 2003;14:588
[48] Liaw CC, Yang YL, Chen M, 
Chang FR, Chen SL, Wu SH, et al. 
Mono-tetrahydrofuran annonaceous 
acetogenins from Annona squamosa 
as cytotoxic agents and calcium ion 
chelators. Journal of Natural Products. 
2008;71:764-771
[49] Yang HJ, Zhang N, Chen JW, Wang 
MY. Two new cytotoxic acetogenins 
from Annona squamosa. Journal of 
Asian Natural Products Research. 
2009;11:250-256
[50] Chen Y, Chen JW, Li X. Cytotoxic 
bistetrahydrofuran annonaceous 
acetogenins from the seeds of Annona 
squamosa. Journal of Natural Products. 
2011;74:2477-2481
[51] Chen Y, Xu SS, Chen JW, Wang Y,  
Xu HQ, Fan NB, et al. Anti-tumor 
activity of Annona squamosa seeds 
extract containing annonaceous 
acetogenin compounds. Journal of 
Ethnopharmacology. 2012;142:462-466
[52] Chen Y, Chem J, Wang Y, Xu S,  
Li X. Six cytotoxic annonaceous 
acetogenins from Annona 
squamosa seeds. Food Chemistry. 
2012;135:960-966
[53] Miao Y, Xu X, Yuan F, Shi Y, 
Chen Y, Chen J, et al. Four cytotoxic 
annonaceous acetogenins from the seeds 
of Annona squamosa. Natural Product 
Research. 2016;30:1273-1279
[54] Pardhasaradhi BV, Reddy M,  
Kumari AM, Ali AL, Khar A. 
Differential cytotoxic effects of 
Annona squamosa seed extracts 
on human tumor cell lines: Role 
of reactive oxygen species and 
glutathione. Journal of Biosciences. 
2005;30:237-244
[55] Nakano D, Ishitsuka K, Kamikawa 
M, Matsuda M, Tsuchihashi R, Okawa 
M, et al. Screening of promising 
chemotherapeutic candidates from 
plants against human adult T-cell 
leukemia/lymphoma. Journal of Natural 
Medicines. 2013;67:894-903
[56] Li XH, Hui YH, Rupprecht JK,  
Liu YM, Wood KV, Smith DL, 
et al. Bullatacin, bullatacinone, 
and squamone, a new bioactive 
acetogenin, from the bark of Annona 
squamosa. Journal of Natural Products. 
1990;53:81-86
[57] Hopp DC, Alali FQ, Gu ZM, 
McLaughlin JL. Three new bioactive 
bis-adjacent THF-ring acetogenins 
from the bark of Annona squamosa. 
Bioorganic & Medicinal Chemistry. 
1998;6:569-575
[58] Sun L, Zhu H, Gan L, Mo J, Feng F, 
Zhou C. Constituents from the bark of 
Annona squamosa and their anti-tumor 
activity. Zhongguo Zhong Yao Z Zhi. 
2012;37:2100-2104
[59] Vilanova NS, Morais SM, Facao MJ, 
Machado LM, Becilaqua CM, Costa IR,  
et al. Leishmanicidal activity and 
cytotoxicity of compounds from 
two Annonacea species cultivated 
in Northeastern Brazil. Revista da 
Sociedade Brasileira de Medicina 
Tropical. 2011;44:567-571
[60] Ma C, Wang Q, Shi Y, Li Y, Wang X,  
Li X, et al. Three new anti-tumor 
annonaceous acetogenins from the seeds 
of Annona squamosa. Natural Product 
Research. 2017;31:2085-2090
[61] Jou B, Remanin P. Antitumor 
constituents from Annona squamosa 
fruit pulp. Medicinal Chemistry 
Research. 2008;17:345-355
[62] Chen YY, Cao YZ, Li FQ, Xl Z, 
Peng CX, Lu JH, et al. Studies on 
anti-hepatoma activity of Annona 
squamosa L. pericarp extract. Bioorganic 
& Medicinal Chemistry Letters. 
2017;27:1907-1910
Pharmacognosy - Medicinal Plants
24
[63] Chen YY, Peng CX, Hu Y, Bu C, 
Guo SC, Li X, et al. Studies on chemical 
constituents and anti-hepatoma effects 
of essential oil from Annona squamosa 
L. pericarp. Natural Product Research. 
2017;31:1308-1308
[64] Chen Y, Shi Y, Ma C, Wang X, Li Y,  
Miao Y, et al. Antitumor activity 
of Annona squamosa. Journal of 
Ethnopharmacology. 2016;193:362-367
[65] Yang RM, Li WM, Hu WJ, Huang 
WH, Zhu CY, Yu JG, et al. Anticancer 
effect of total annonaceous acetogenins 
on hepatocarcinoma. Chinese 
Journal of Integrative Medicine. 
2015;21:682-688
[66] Thakkar JH, Solanki HK, Tripathi P, 
Patel NJ, Jani GK. Evaluation of 
antimutagenic potential of Annona 
squamosa leaf extract. Elixir Human 
Physiology. 2011;31:1960-1965
[67] Suresh K, Manoharn S, Blessy D. 
Protective role of Annona squamosa 
Linn bark extracts in DMBA induced 
genotoxicity. Kathmandu University 
Medical Journal. 2008;6:364-369
[68] Suresh K, Manoharan S, 
Panjamurthy K, Kavitha K.  
Chemoprotective and 
antilipidperoxidative efficacy of Annona 
squamosa bark extracts in experimental 
oral carcinogenesis. Pakistan Journal of 
Biological Sciences. 2006;9:2600-2605
[69] Joshi RK. GC/MS analysis of 
the essential oil of Vernonia cinerea. 
Natural Product Communications. 
2015;10:1319-1320
[70] Jaworski J, Cahoon EB. Industrial 
oils from transgenic plants. 
Current Opinion in Plant Biology. 
2003;6:178-184
[71] Wongwiwatthananukit S, 
Benjanakaskul P, Songsak T, 
Suwanamajo S, Verachai V. Efficacy 
of Vernonia cinerea for smoking 
cessation. Journal of Health Research. 
2009;23:31-36
[72] Bin Sayeed MS, Mostofa AG, 
Ferdous FM, Islam MS. A randomized, 
placebo-controlled, crossover study 
of an herbal preparation containing 
Vernonia cinerea in the treatment of 
type 2 diabetes. Journal of Alternative 
and Complementary Medicine. 
2013;19:767-771
[73] Puttarak P, Pornpanyanukul P,  
Meetam T, Bunditanukul K, 
Chaiyakunapruk N. Efficacy and 
safety of Vernonia cinerea (L.) Less. for 
smoking cessation: A systematic review 
and meta-analysis of randomized 
controlled trials. Complementary 
Therapies in Medicine. 2018;37:37-42
[74] Khay M, Toeng P, Mahiou-
Leddet V, Mabrouki F, Sothea K, 
Ollivier E, et al. HPLC analysis and 
cytotoxic activity of Vernonia cinerea. 
Natural Product Communications. 
2012;7:1259-1262
[75] Guha G, Rajkumar V, Ashok Kumar 
R, Mathew L. Therapeutic potential 
of polar and non-polar extracts 
of Cyanthillium cinereum in vitro. 
Evidence-based Complementary 
and Alternative Medicine. 
2011;2011:784826. DOI: 10.1093/ecam/
nep155
[76] Appadath Beeran A, Maliyakkal N,  
Rao CM, Udupa N. The enriched 
fraction of Vernonia cinerea L. induces 
apoptosis and inhibits multi-drug 
resistance transporters in human 
epithelial cancer cells. Journal of 
Ethnopharmacology. 2014;158(Pt A): 
33-42
[77] Pratheeshkumar P, Kuttan G. 
Modulation of cytotoxic T lymphocyte, 
natural killer cell, antibody-dependent 
cellular cytotoxicity, and antibody-
dependent complement-mediated 
cytotoxicity by Vernonia cinerea L. 
and vernolide-A in BALB/c mice via 
25
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
enhanced production of cytokines IL-2 
and IFN-γ. Immunopharmacology and 
Immunotoxicology. 2012;34:46-55
[78] Shoaib M, Shah I, Ali N, Adhikari A, 
Tahir MN, Shah SWA, et al. 
Sesquiterpene lactone! a promising 
antioxidant, anticancer and moderate 
antinociceptive agent from Artemisia 
macrocephala Jacquem. BMC 
Complementary and Alternative 
Medicine. 2017;17:27. DOI: 10.1186/
s12906-016-1517-y
[79] Pratheeshkumar P, Kuttan G. 
Modulation of immune response 
by Vernonia cinerea L. inhibits the 
proinflammatory cytokine profile, 
iNOS, and COX-2 expression in 
LPS-stimulated macrophages. 
Immunopharmacology and 
Immunotoxicology. 2011;33:73-83
[80] Rajakumar G, Abdul Rahuman A,  
Priyamvada B, Gopiesh Khanna V, 
Kishore Kumar D, Sujin PJ. Eclipta 
prostrata leaf aqueous extract 
mediated synthesis of titanium dioxide 
nanoparticles. Materials Letters. 
2012;68:115-117
[81] Tamimi H, Shishesaz MR, 
Farzam M, Jafari D. A review on 
nanoparticles of titanium dioxide: 
Characteristics, methods of synthesis 
and their application in organic 
coatings. International Journal of 
Advanced Biotechnology and Research. 
2016;7:1226-1231
[82] Chung IM, Rajakumar G, Lee JH, 
Kim SH, Thiruvengadam M.  
Ethnopharmacological uses, 
phytochemistry, biological activities, 
and biotechnological applications of 
Eclipta prostrata. Applied Microbiology 
and Biotechnology. 2017;101:5247-5257
[83] Mithun NM, Shashidhara S, 
Vivek Kumar R. Eclipta alba (L.). 
A review on its phytochemical 
and pharmacological profile. 
Pharmacology. 2011;1:345-357
[84] Lee MK, Ha NR, Yang H, Sung SH, 
Kim GH, Kim YC. Antiproliferative 
activity of triterpenoids from Eclipta 
prostrata on hepatic stellate cells. 
Phytomedicine. 2008;15:775-780
[85] Liu QM, Zhao HY, Zhong XK,  
Jiang JG. Eclipta prostrata L. 
phytochemicals: Isolation, structure 
elucidation, and their antitumor 
activity. Food and Chemical Toxicology. 
2012;50:4016-4022
[86] Chaudhary H, Dhuna V, Singh J, 
Kamboj SS, Seshadri S. Evaluation of 
hydro-alcoholic extract of Eclipta alba 
for its anticancer potential: An in vitro 
study. Journal of Ethnopharmacology. 
2011;136:363-367
[87] Yadav NK, Arya RK, Dev K, 
Sharma C, Hossain Z, Meena S, 
et al. Alcoholic extract of Eclipta 
alba shows in vitro antioxidant 
and anticancer activity without 
exhibiting toxicological effects. 
Oxidative Medicine and Cellular 
Longevity. 2017;2017:9094641. DOI: 
10.1155/2017/9094641
[88] Chauhan N, Singh D, Painuli RM. 
Screening of bioprotective properties 
and phytochemical analysis of various 
extracts of Eclipta alba whole plant. 
International Journal of Pharmacy 
and Pharmaceutical Sciences. 
2012;4:554-560
[89] Gupta M, Mazumdera UK, Haldar 
PK, Kandar CC, Manikanda L, Senthil 
GP. Anticancer activity of Indigofera 
aspalathoides and Wedelia calendulaceae 
in Swiss albino mice. Iranian 
Journal of Pharmaceutical Research. 
2007;6:141-145
[90] Kim HY, Kim HM, Ryu B, Lee JS,  
Choi JH, Jang DS. Constituents of 
the aerial parts of Eclipta prostrata 
and their cytotoxicity on human 
ovarian cancer cells in vitro. 
Archives of Pharmacal Research. 
2015;38:1963-1969
Pharmacognosy - Medicinal Plants
26
[91] Khanna VG, Kannabiran K. 
Anticancer-cytotoxic activity of 
saponins isolated from the leaves of 
Gymnema sylvestre and Eclipta alba on 
HeLa cells. International Journal of 
Green Pharmacy. 2009;1:227-229
[92] Cho YJ, Woo JH, Lee JS, Jang DS, 
Lee KT, Choi JH. Eclalbasaponin II 
induces autophagic and apoptotic cell 
death in human ovarian cancer cells. 
Journal of Pharmacological Sciences. 
2016;132:6-14
[93] Lirdprapamongkol K, Kramb JP, 
Chokchaichamnankit D, Srisomsap C,  
Surarit R, Sila-Asna M, et al. Juice 
of Eclipta prostrata inhibits cell 
migration in vitro and exhibits anti-
angiogenic activity in vivo. In Vivo. 
2008;22:363-368
[94] Ali F, Khan R, Khan AQ , 
Lateef MA, Maqbool T, Sultana S. 
Assessment of augmented immune 
surveillance and tumor cell death 
by cytoplasmic stabilization of p53 
as a chemopreventive strategy of 3 
promising medicinal herbs in murine 
2-stage skin carcinogenesis. Integrative 
Cancer Therapies. 2014;13:351-367
[95] Dickers KJ, Bradberry SM, Rice P, 
Griffiths GD, Vale JA. Abrin poisoning. 
Toxicological Reviews. 2003;22:137-142
[96] Inglett GE, May JF. Tropical plants 
with unusual taste properties. Economic 
Botany. 1968;22:326-331
[97] Verma D, Tiwari SS, Srivastava S,  
Rawat A. Pharmacognostical 
evaluation and phytochemical 
standardization of Abrus precatorius 
L. seeds. Natural Product Sciences. 
2011;17:51-57
[98] Garaniya N, Bapodra A.  
Ethnobotanical and 
phytopharmacological potential of 
Abrus precatorius L.: A review. Asian 
Pacific Journal of Tropical Biomedicine. 
2014;4(Suppl 1):S27-S34
[99] Gadadhar S, Karande AA. Abrin 
immunotoxin: Targeted cytotoxicity and 
intracellular trafficking pathway. PLoS 
One. 2013;8(3):e58304
[100] Panneerselvam K, Lin SC, Liu CL, 
Liaw YC, Lin JY, Lu TH. Crystallization 
of agglutinin from the seeds of Abrus 
precatorius. Acta Crystallographica. 
Section D, Biological Crystallography. 
2000;56:898-899
[101] Bhutia SK, Mallick SK, Stevens SM,  
Prokai L, Vishwanatha JK, Maiti TK. 
Induction of mitochondria-dependent 
apoptosis by Abrus agglutinin derived 
peptides in human cervical cancer cells. 
Toxicology In Vitro. 2008;22:344-351
[102] Gul MZ, Ahmad F, Kondapi AK, 
Qureshi IA, Ghazi IA. Antioxidant 
and antiproliferative activities of 
Abrus precatorius leaf extracts—An in 
vitro study. BMC Complementary and 
Alternative Medicine. 2013;13:53. DOI: 
10.1186/1472-6882-13-53
[103] Lébri M, Tilaoui M, Bahi C, 
Achibat H, Akhramez S, Fofié YBN, 
et al. Phytochemical analysis and in vitro 
anticancer effect of aqueous extract 
of Abrus precatorius Linn. Der Pharma 
Chemica. 2015;7:112-117
[104] Shafi Sofi M, Sateesh MK, Bashir M, 
Harish G, Lakshmeesha TR, Vedashree 
S, et al. Cytotoxic and pro-apoptotic 
effects of Abrus precatorius L. on 
human metastatic breast cancer cell 
line, MDA-MB-231. Cytotechnology. 
2013;65:407-417
[105] Reddy VV, Sirsi M. Effect of  
Abrus precatorius L. on experimental 
tumors. Cancer Research. 
1969;29:1447-1451
[106] Bhutia SK, Mallick SK, Maiti S, 
Maiti TK. Antitumor and proapoptotic 
effect of Abrus agglutinin derived 
peptide in Dalton's lymphoma tumor 
model. Chemico-Biological Interactions. 
2008;174:11-18
27
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
[107] Bhutia SK, Mallick SK, Maiti TK. In 
vitro immunostimulatory properties 
of Abrus lectins derived peptides in 
tumor bearing mice. Phytomedicine. 
2009;16:776-782
[108] Anbu J, Ravichandiran V, 
Sumithra M, Chowdary SB, Kumar 
S, Kannadhasan R, et al. Anticancer 
activity of petroleum ether extract 
of Abrus precatorius on Ehrlich ascitis 
carcinoma in mice. International 
Journal of Pharma and Bio Sciences. 
2011;2:24-31
[109] Shionoya H, Arai H, Koyanagi N, 
Ohtake S, Kobayashi H, Kodama T, et al. 
Induction of antitumor immunity by 
tumor cells treated with abrin. Cancer 
Research. 1982;42:2872-2876
[110] Ramnath V, Kuttan G, Kuttan 
R. Immunopotentiating activity of 
abrin, a lectin from Abrus precatorius 
Linn. Indian Journal of Experimental 
Biology. 2002;40:910-913
[111] Ghosh D, Bhutia SK, Mallick SK, 
Banerjee I, Maiti TK. Stimulation of 
murine B and T lymphocytes by native 
and heat-denatured Abrus agglutinin. 
Immunobiology. 2009;214:227-234
[112] Van Andel T. The diverse uses of 
fish-poison plants in northwest Guyana. 
Economic Botany. 2000;54:500-512
[113] Fukami J, Shishido T, Fukunaga 
K, Casida JE. Oxidative metabolism of 
rotenone in mammals, fish, and insects 
and its relation to selective toxicity. 
Journal of Agricultural and Food 
Chemistry. 1969;17:1217-1226
[114] Qureshi R, Bhatti GR, Memon 
RA. Ethnomedicinal uses of herbs 
from northern part of NARA desert, 
Pakistan. Pakistan Journal of Botany. 
2010;42:839-851
[115] Vasconcelos JN, Lima JQ, de Lemos 
TLG, Oliveira MCF, Almeida MMB, 
Andrade-Neto M, et al. Estudo químico 
e biologico de Tephrosia toxicaria Pers. 
(Chemical and biological study of 
Tephrosia toxicaria Pers.). Quím Nova. 
2009;32:382-386
[116] Touqeer S, Saeed MA, Ajaib M. A 
review on the phytochemistry and 
pharmacology of genus Tephrosia. 
Phytopharmacology. 2013;4:598-637
[117] Chen Y, Yan T, Gao C, Cao W, 
Huang R. Natural products from 
the genus Tephrosia. Molecules. 
2014;19:1432-1458
[118] Adinarayana K, Jayaveera KN, 
Madhu Katyayani B, Mallikarjuna Rao P.  
Growth inhibition and induction of 
apoptosis in estrogen receptor positive 
and negative human breast carcinoma 
cells by Tephrosia calophylla roots. 
Pharmaceutical Chemistry Journal. 
2009;3:35-41
[119] Gulecha V, Sivakuma T. Anticancer 
activity of Tephrosia purpurea and Ficus 
religiosa using MCF 7 cell lines. Asian 
Pacific Journal of Tropical Medicine. 
2011;4:526-529
[120] Nondo RS, Mbwambo ZH, 
Kidukuli AW, Innocent EM, Mihale MJ, 
Erasto P, et al. Larvicidal, 
antimicrobial and brine shrimp 
activities of extracts from Cissampelos 
mucronata and Tephrosia villosa 
from coast region, Tanzania. BMC 
Complementary and Alternative 
Medicine. 2011;11:33-37
[121] Shanmugapriya R, Umamaheswari 
G, Thirunavukkarasu P, Renugadevi 
G, Ramanathan T. Cytotoxic effect of 
Tephrosia purpurea extracts on HeLa 
cervical cancerous cell line. Inventi 
Rapid: Molecular Pharmacology 2011;2. 
Article ID “Inventi:mp/49/11”
[122] Subhadra S, Kanacharalapalli VR, 
Ravindran VK, Parre SK, Chintala S, 
Thatipally R. Comparative toxicity 
assessment of three Tephrosia species 
on Artemia salina and animal cell lines. 
Pharmacognosy - Medicinal Plants
28
Journal of Natural Pharmaceuticals. 
2011;2:143-148
[123] Khalighi-Sigaroodi F, Ahvazi M,  
Hadjiakhoondi A, Taghizadeh M, 
Yazdani D, Khalighi-Sigaroodi S, et al. 
Cytotoxicity and antioxidant activity of 
23 plant species of Leguminosae family. 
Iranian Journal of Pharmaceutical 
Research. 2012;11:295-302
[124] Padmapriya R, Gayathri L, Ronsard 
L, Akbarsha MA, Raveendran R. In 
vitro antiproliferative effect of Tephrosia 
purpurea on human hepatocellular 
carcinoma cells. Pharmacognosy 
Magazine. 2017;13(Suppl 1):S16-S21
[125] Ganapaty S, Srilakshmi GVK, 
Pannakal ST, Rahman H, Laatsch H, 
Brun R. Cytotoxic benzil and coumestan 
derivatives from Tephrosia calophylla. 
Phytochemistry. 2009;70:95-99
[126] Ganapaty S, Srilakshmi GVK,  
Thomas PS, Rajeswari NR, 
Ramakrishna S. Cytotoxicity and 
antiprotozoal activity of flavonoids 
from three Tephrosia species. Journal of 
Natural Remedies. 2009;9:202-208
[127] Hassan LE, Ahamed MB, Majid AS, 
Baharetha HM, Muslim NS, Nassar ZD, 
et al. Correlation of antiangiogenic, 
antioxidant and cytotoxic activities 
of some Sudanese medicinal plants 
with phenolic and flavonoid contents. 
BMC Complementary and Alternative 
Medicine. 2014;14:406. DOI: 
10.1186/1472-6882-14-406
[128] Hassan LEA, Iqbal MA, 
Dahham SS, Tabana YM, Ahamed 
MBK, Majid AMSA. Colorectal, 
prostate and pancreas human cancers 
targeted bioassay-guided isolations 
and characterization of chemical 
constituents from Tephrosia apollinea. 
Anti-Cancer Agents in Medicinal 
Chemistry. 2017;17:590-598
[129] Jang DS, Park EJ, Kang YH, 
Hawthorne ME, Vigo JS, Graham JG, 
et al. Potential cancer chemopreventive 
flavonoids from the stems of Tephrosia 
toxicaria. Journal of Natural Products. 
2003;66:1166-1170
[130] Saleem M, Ahmed S, Alam A,  
Sultana S. Tephrosia purpurea 
alleviates phorbol ester-induced 
tumor promotion response in murine 
skin. Pharmacological Research. 
2001;43:135-144
[131] Hussain T, Siddiqui HH, Fareed S, 
Vijayakumar M, Rao CV.  
Chemopreventive evaluation 
of Tephrosia purpurea against 
N-nitrosodiethylamine-induced 
hepatocarcinogenesis in Wistar rats. The 
Journal of Pharmacy and Pharmacology. 
2012;64:1195-1205
[132] Bright EO, Okusanya BA. 
Infestation of economic plants in 
Badeggi by Tapinanthus dodoneifolius 
(DC) Danser and Tapinanthus globiferus 
(A. Rich) Van Tiegh. Nigerian Journal of 
Weed Science. 1998;11:51-56
[133] Roth I, Lindorf H. South American 
Medicinal Plants. Botany, Remedial 
Properties and General Use. Berlin: 
Springer Verlag; 2002
[134] Yazbek PB, Tezoto J, Cassas F,  
Rodrigues E. Plants used during 
maternity, menstrual cycle and 
other women's health conditions 
among Brazilian cultures. Journal of 
Ethnopharmacology. 2016;179:310-331
[135] Lindholm P. Cytotoxic compounds 
of plant origin—Biological and chemical 
diversity. [PhD thesis]. Uppsala: Faculty 
of Pharmacy; 2005
[136] Mary KT, Girija K, Ramadasan K. 
Partial purification of tumour-reducing 
principle from Helicanthis elasticus 
(Fam. Loranthaceae). Cancer Letters. 
1994;81:53-57
[137] Fernandez T, Wagner ML, Varela 
BG, Ricco RA, Hajos SE, Gurni AA, 
29
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
et al. Study of an Argentine mistletoe, 
the hemiparasite Ligaria cuneifolia (R. 
et P.) Tiegh. (Loranthaceae). Journal of 
Ethnopharmacology. 1998;62:25-34
[138] Winarno H. Antiproliferative 
activity of octadeca-8,10,12-triynoic 
acid against human cancer cell lines. 
Benia Biologi. 2009;9:343-348
[139] Yoon TJ, Yoo YC, Kang TB, 
Shimazaki K, Song SK, Lee KH, et al. 
Lectins isolated from Korean mistletoe 
(Viscum album coloratum) induce 
apoptosis in tumor cells. Cancer Letters. 
1999;136:33-40
[140] Rios MY, Salina D, Villarreal ML. 
Cytotoxic activity of moronic acid and 
identification of the new triterpene 
3,4-seco-olean-18-ene-3,28-dioic acid 
from Phoradendron reichenbachianum. 
Planta Medica. 2001;67:443-446
[141] Sadik G, Islam R, Rahman MM, 
Khondkar P, Rashid MA, Sarker SD.  
Antimicrobial and cytotoxic 
constituents of Loranthus globosus. 
Fitoterapia. 2003;74:308-311
[142] Kim YK, Kim YS, Choi SU, Ryu SY.  
Isolation of flavonol rhamnosides 
from Loranthus tanakae and cytotoxic 
effect of them on human tumor cell 
lines. Archives of Pharmacal Research. 
2004;27:44-47
[143] Zhao YL, Wang XY, Sun LX, 
Fan RH, Bi KS, Yu ZG. Cytotoxic 
constituents of Viscum coloratum. 
Zeitschrift für Naturforschung.  
Section C. 2012;67:129-134
[144] Cerdá Zolezzi P, Fernández T, 
Aulicino P, Cavaliere V, Greczanik S, 
Caldas Lopes E, et al. Ligaria cuneifolia 
flavonoid fractions modulate cell growth 
of normal lymphocytes and tumor cells 
as well as multidrug resistant cells. 
Immunobiology. 2005;209:737-749
[145] Murwani R. Indonesian tea 
mistletoe (Scurrula oortiana) stem 
extract increases tumour cell sensitivity 
to tumour necrosis factor alpha 
(TNFalpha). Phytotherapy Research. 
2003;17:407-409
[146] Elsyana V, Bintang M, 
Priosoeryanto BP. Cytotoxicity 
and antiproliferative activity assay 
of clove mistletoe (Dendrophthoe 
pentandra (L.) Miq.) leaves extracts. 
Advances in Pharmacological 
Sciences. 2016;2016:3242698. DOI: 
10.1155/2016/3242698
[147] Kumar N, Biswas S, Mathew AE, 
Varghese S, Mathew JE, Nandakumar K, 
et al. Pro-apoptotic and cytotoxic 
effects of enriched fraction of Elytranthe 
parasitica (L.) Danser against HepG2 
hepatocellular carcinoma. BMC 
Complementary and Alternative 
Medicine. 2016;16:420
[148] Ohashi K, Winarno H, Mukai M, 
Shibuya H. Preparation and cancer 
cell invasion inhibitory effects of 
C16-alkynic fatty acids. Chemical 
and Pharmaceutical Bulletin (Tokyo). 
2003;51:463-466
[149] Heitzman ME, Neto CC, Winiarz 
E, Vaisberg AJ, Hammond GB. 
Ethnobotany, phytochemistry and 
pharmacology of Uncaria (Rubiaceae). 
Phytochemistry. 2005;66:5-29
[150] Sandoval M, Okuhama NN, Zhang 
XJ, Condezo LA, Lao J, Angeles FM, 
et al. Anti-inflammatory and antioxidant 
activities of cat's claw (Uncaria 
tomentosa and Uncaria guianensis) are 
independent of their alkaloid content. 
Phytomedicine. 2002;9:325-337
[151] Lee KK, Zhou BN, Kingston DG, 
Vaisberg AJ, Hammond GB. Bioactive 
indole alkaloids from the bark of 
Uncaria guianensis. Planta Medica. 
1999;65:759-760
[152] Laus G. Advances in chemistry 
and bioactivity of the genus Uncaria. 
Phytotherapy Research. 2004;18:259-274
Pharmacognosy - Medicinal Plants
30
[153] Miller MJ, Mehta K, Kunte S, 
Raut V, Gala J, Dhumale R, et al. Early 
relief of osteoarthritis symptoms 
with a natural mineral supplement 
and a herbomineral combination: 
A randomized controlled trial 
[ISRCTN38432711]. Journal of 
Inflammation (London). 2005;2:11
[154] Mehta K, Gala J, Bhasale S, 
Naik S, Modak M, Thakur H, et al. 
Comparison of glucosamine sulfate 
and a polyherbal supplement for 
the relief of osteoarthritis of the 
knee: A randomized controlled 
trial [ISRCTN25438351]. BMC 
Complementary and Alternative 
Medicine. 2007;7:34
[155] Mur E, Hartig F, Eibl G, Schirmer 
M. Randomized double blind trial of an 
extract from the pentacyclic alkaloid-
chemotype of Uncaria tomentosa for 
the treatment of rheumatoid arthritis. 
The Journal of Rheumatology. 
2002;29:678-681
[156] Del Grossi Moura M, Lopes LC,  
Biavatti MW, Kennedy SA, de 
Oliveira E, Silva MC, et al. Oral 
herbal medicines marketed in Brazil 
for the treatment of osteoarthritis: 
A systematic review and meta-
analysis. Phytotherapy Research. 
2017;31:1676-1685
[157] Bacher N, Tiefenthaler M, Sturm S,  
Stuppner H, Ausserlechner M, 
Kofler R. Oxindole alkaloids from 
Uncaria tomentosa induce apoptosis 
in proliferating, G0/G1-arrested and 
bcl-2-expressing acute lymphoblastic 
leukaemia cells. British Journal of 
Haematology. 2006;132:615-622
[158] Garcia Prado E, Garcia Gimenez 
MD, De la Puerta Vazquez R, 
Espartero Sanchez JL, Saenz Rodriguez 
MT. Antiproliferative effects of 
mitraphylline, a pentacyclic oxindole 
alkaloid of Uncaria tomentosa on human 
glioma and neuroblastoma cell lines. 
Phytomedicine. 2007;14:280-284
[159] García Giménez D, García Prado E, 
Sáenz Rodríguez T, Fernández Arche A,  
De la Puerta R. Cytotoxic effect of 
the pentacyclic oxindole alkaloid 
mitraphylline isolated from Uncaria 
tomentosa bark on human Ewing’s 
sarcoma and breast cancer cell lines. 
Planta Medica. 2010;76:133-136
[160] Pilarski R, Filip B, Wietrzyk J, 
Kuras M, Gulewicz K. Anticancer 
activity of the Uncaria tomentosa DC. 
preparations with different oxindole 
alkaloid composition. Phytomedicine. 
2010;17:1133-1139
[161] Urdanibia I, Michelangeli F, 
Ruiz MC, Milano B, Taylor P. Anti-
inflammatory and antitumoural 
effects of Uncaria guianensis bark. 
Journal of Ethnopharmacology. 
2013;150:1154-1162
[162] Budán F, Szabó I, Varjas T, 
Nowrasteh G, Dávid T, Gergely 
P, et al. Mixtures of Uncaria and 
Tabebuia extracts are potentially 
chemopreventive in CBA/Ca mice: A 
long-term experiment. Phytotherapy 
Research. 2011;25:493-500
[163] De Paula LC, Fonseca F, Perazzo F, 
Cruz FM, Cubero D, Trufelli DC, et al. 
Uncaria tomentosa (cat's claw) improves 
quality of life in patients with advanced 
solid tumors. Journal of Alternative 
and Complementary Medicine. 
2015;21:22-30
[164] Araújo MCS, Farias ILG, 
Gutierres J, Dalmora SL, Flores N, 
Farias J, et al. Uncaria tomentosa—
Adjuvant treatment for breast 
cancer: Clinical trial. Evidence-based 
Complementary and Alternative 
Medicine. 2012;2012:676984. DOI: 
10.1155/2012/676984
[165] Farias ILG, Araújo MCS, 
Farias JG, Rossato LV, Elsenbach LI, 
Dalmora SL, et al. Uncaria tomentosa 
for reducing side effects caused 
by chemotherapy in CRC patients: 
31
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
Clinical trial. Evidence-based 
Complementary and Alternative 
Medicine. 2012;2012:892182. DOI: 
10.1155/2012/892182
[166] Alves IABS, Miranda HM, Soares 
LAL, Randau KP. Simaroubaceae 
family: Botany, chemical composition 
and biological activities. Revista 
Brasileira de Farmacognosia. 
2014;24:481-501
[167] Almeida MMB, Arriaga AMC, 
Santos AKL, Lemos TLG, Braz-
Filho R, Vieira IJC. Ocorrência e 
atividade biológica de quassinóides 
da última década (Occurrence and 
biological activity of quassinoids 
in the last decade). Quimica Nova. 
2007;30:935-951
[168] Vikas B, Akhil BS, Suja SR, 
Sujathan K. An exploration of 
phytochemicals from Simaroubaceae. 
Asian Pacific Journal of Cancer 
Prevention. 2017;18:1765-1767
[169] Showalter HDH. Progress in the 
synthesis of canthine alkaloids and ring-
truncated congeners. Journal of Natural 
Products. 2013;76:455-467
[170] Diehl C, Ferrari A. Superiority 
of Quassia amara 4% cream over 
metronidazole 0.75% cream in the 
treatment of rosacea: A randomized, 
double-blinded trial. Journal of Clinical 
and Cosmetic Dermatology. 2017;1. 
DOI: 10.16966/2576-2826.117
[171] Kupchan SM, Streelman DR. 
Quassimarin, a new antileukemic 
quassinoid from Quassia amara. 
The Journal of Organic Chemistry. 
1976;41:3481-3482
[172] Kitagawa I, Mahmud T, Yokota K, 
Nakagawa S, Mayumi T, Kobayashi M,  
et al. Indonesian medicinal plants. 
XVII. Characterization of quassinoids 
from the stems of Quassia indica. 
Chemical and Pharmaceutical Bulletin 
(Tokyo). 1996;44:2009-2014
[173] Cachet N, Hoakwie F, Bertani S, 
Bourdy G, Deharo E, Stien D, et al. 
Antimalarial activity of simalikalactone 
E, a new quassinoid from Quassia amara 
L. (Simaroubaceae). Antimicrobial 
Agents and Chemotherapy. 
2009;53:4393-4398
[174] Houël E, Bertani S, Bourdy G, 
Deharo E, Jullian V, Valentin A, et al. 
Quassinoid constituents of Quassia 
amara L. leaf herbal tea. Impact on its 
antimalarial activity and cytotoxicity. 
Journal of Ethnopharmacology. 
2009;126:114-118
[175] Murakami C, Fukamiya N, 
Tamura S, Okano M, Bastow 
KF, Tokuda H, et al. Multidrug-
resistant cancer cell susceptibility 
to cytotoxic quassinoids, and 
cancer chemopreventive effects of 
quassinoids and canthin alkaloids. 
Bioorganic & Medicinal Chemistry. 
2004;12:4963-4968
[176] Rivero-Cruz JF, Lezutekong R, 
Lobo-Echeverri T, Ito A, Mi Q, Chai HB, 
et al. Cytotoxic constituents of the twigs 
of Simarouba glauca collected from a 
plot in southern Florida. Phytotherapy 
Research. 2005;19:136-140
[177] Jiang XM, Zhou Y. Canthin-6-one 
alkaloids from Picrasma quassioides 
and their cytotoxic activity. Journal 
of Asian Natural Products Research. 
2008;10:1009-1012
[178] Usami Y, Nakagawa-Goto K, 
Lang JY, Kim Y, Lai CY, Goto M, et al. 
Antitumor agents. 282. 2′-(R)-O-
acetylglaucarubinone, a quassinoid 
from Odyendyea gabonensis as a potential 
anti-breast and anti-ovarian cancer 
agent. Journal of Natural Products. 
2010;73:1553-1558
[179] Shields M, Niazi U, Badal S, Yee T,  
Sutcliffe MJ, Delgoda R. Inhibition 
of CYP1A1 by quassinoids found 
in Picrasma excelsa. Planta Medica. 
2009;75:137-141
Pharmacognosy - Medicinal Plants
32
[180] Wiseman CL, Yap HY, Bedikian AY, 
Bodey GP, Blumenschein GR. Phase II 
trial of bruceantin in metastatic breast 
carcinoma. American Journal of Clinical 
Oncology. 1982;5:389-391
[181] Arseneau JC, Wolter JM, 
Kuperminc M, Ruckdeschel JC. A 
Phase II study of bruceantin (NSC-
165, 563) in advanced malignant 
melanoma. Investigational New Drugs. 
1983;1:239-242
[182] Shan GY, Zhang S, Li GW, 
Chen YS, Liu XA, Wang JK. Clinical 
evaluation of oral Fructus bruceae 
oil combined with radiotherapy for 
the treatment of esophageal cancer. 
Chinese Journal of Integrative Medicine. 
2011;17:933-936
[183] Grant KL, Lutz RB. Alternative 
therapies: Ginger. American Journal 
of Health-System Pharmacy. 
2000;57:945-947
[184] An K, Zhao D, Wang Z, Wu 
J, Xu Y, Xiao G. Comparison of 
different drying methods on Chinese 
ginger (Zingiber officinale Roscoe): 
Changes in volatiles, chemical 
profile, antioxidant properties, and 
microstructure. Food Chemistry. 
2016;197(Part B:1292-1300
[185] Rahmani AH, Shabrmi FM, Aly 
SM. Active ingredients of ginger as 
potential candidates in the prevention 
and treatment of diseases via 
modulation of biological activities. 
International Journal of Physiology, 
Pathophysiology and Pharmacology. 
2014;6:125-136
[186] Gupta R, Singh PK, Singh R, 
Singh RL. Pharmacological activities of 
Zingiber officinale (ginger) and its active 
ingredients: A review. International 
Journal of Innovation Science and 
Research. 2016;4:1-18
[187] Lee E, Surh YJ. Induction of 
apoptosis in HL60 cells by pungent 
vanilloids, [6]-gingerol and [6]-paradol. 
Cancer Letters. 1998;134:163-168
[188] Keum YS, Kim J, Lee KH, Park 
KK, Surh YJ, Lee JM, et al. Induction 
of apoptosis and caspase-3 activation 
by chemopreventive [6]-paradol and 
structurally related compounds in KB 
cells. Cancer Letters. 2002;177:41-47
[189] Park YJ, Wen J, Bang S, Park 
SW, Song SY. [6]-Gingerol induces 
cell cycle arrest and cell death of 
mutant p53-expressing pancreatic 
cancer cells. Yonsei Medical Journal. 
2006;47:688-697
[190] Ishiguro K, Ando T, Maeda 
O, Ohmiya N, Niwa Y, Kadomatsu 
K, et al. Ginger ingredients reduce 
viability of gastric cancer cells via 
distinct mechanisms. Biochemical and 
Biophysical Research Communications. 
2007;362:218-223
[191] Rhode J, Fogoros S, Zick S, Wahl 
H, Griffith KA, Huang J, et al. Ginger 
inhibits cell growth and modulates 
angiogenic factors in ovarian cancer 
cells. BMC Complementary and 
Alternative Medicine. 2007;7:44. DOI: 
10.1186/1472-6882-7-44
[192] Kim JS, Lee SI, Park HW, Yang 
JH, Shin TY, Kim YC, et al. Cytotoxic 
components from the dried rhizomes of 
Zingiber officinale Roscoe. Archives of 
Pharmacal Research. 2008;31:415-418
[193] Lee SH, Cekanova M, Baek SJ. 
Multiple mechanisms are involved in 
6-gingerol-induced cell growth arrest 
and apoptosis in human colorectal 
cancer cells. Molecular Carcinogenesis. 
2008;47:197-208
[194] Brown AC, Shah C, Liu J, Pham 
JT, Zhang JG, Jadus MR. Ginger's 
(Zingiber officinale Roscoe) inhibition 
of rat colonic adenocarcinoma cells 
proliferation and angiogenesis 
in vitro. Phytotherapy Research. 
2009;23:640-645
33
Anticancer Activity of Uncommon Medicinal Plants from the Republic of Suriname: Traditional…
DOI: http://dx.doi.org/10.5772/intechopen.82280
[195] Sang S, Hong J, Wu H, Liu J, Yang 
CS, Pan MH, et al. Increased growth 
inhibitory effects on human cancer 
cells and anti-inflammatory potency of 
shogaols from Zingiber officinale relative 
to gingerols. Journal of Agricultural and 
Food Chemistry. 2009;57:10645-10650
[196] Gan FF, Nagle AA, Ang X, Ho 
OH, Tan SH, Yang H, et al. Shogaols 
at proapoptotic concentrations induce 
G(2)/M arrest and aberrant mitotic 
cell death associated with tubulin 
aggregation. Apoptosis. 2011;16:856-867
[197] Tan BS, Kang O, Mai CW, 
Tiong KH, Khoo AS, Pichika MR, 
et al. 6-Shogaol inhibits breast 
and colon cancer cell proliferation 
through activation of peroxisomal 
proliferator activated receptor gamma 
(PPARgamma). Cancer Letters. 
2013;336:127-139
[198] Surh YJ, Park KK, Chun KS, 
Lee LJ, Lee E, Lee SS. Antitumor 
promoting activities of selected 
pungent phenolic substances present 
in ginger. Journal of Environmental 
Pathology, Toxicology and Oncology. 
1999;18:131-139
[199] Kim M, Miyamoto S, Yasui Y, 
Oyama T, Murakami A, Tanaka T.  
Zerumbone, a tropical ginger 
sesquiterpene, inhibits colon and lung 
carcinogenesis in mice. International 
Journal of Cancer. 2009;124:264-271
[200] Lee E, Park KK, Lee JM, Chun 
KS, Kang JY, Lee SS, et al. Suppression 
of mouse skin tumor promotion and 
induction of apoptosis in HL-60 
cells by Alpina oxyphylla Miquel 
(Zingiberaceae). Carcinogenesis. 
1998;19:1337-1381
[201] Jeong CH, Bode AM, Pugliese A,  
Cho YY, Kim HG, Shim JH, et al. 
[6]-Gingerol suppresses colon cancer 
growth by targeting leukotriene 
A4 hydrolase. Cancer Research. 
2009;69:5584-5591
[202] Wu H, Hsieh MC, Lo CY, Liu CB, 
Sang S, Ho CT, et al. 6-Shogaol is more 
effective than 6-gingerol and curcumin 
in inhibiting 12-O-tetradecanoylphorbol 
13-acetate induced tumor promotion 
in mice. Molecular Nutrition & Food 
Research. 2010;54:1296-1306
[203] Vinothkumar R, Sudha M, Nalini N. 
Chemopreventive effect of zingerone 
against colon carcinogenesis induced 
by 1,2-dimethylhydrazine in rats. 
European Journal of Cancer Prevention. 
2014;23:361-371
[204] Ling H, Yang H, Tan SH, Chui 
WK, Chew EH. 6-Shogaol, an active 
constituent of ginger, inhibits breast 
cancer cell invasion by reducing matrix 
metalloproteinase-9 expression via 
blockade of nuclear factor-kappa 
B activation. British Journal of 
Pharmacology. 2010;161:1763-1777
[205] Núñez-Sánchez MA, González-
Sarrías A, Romo-Vaquero M, García-
Villalba R, Selma MV, Tomás-Barberán 
FA, et al. Dietary phenolics against 
colorectal cancer—From promising 
preclinical results to poor translation 
into clinical trials: Pitfalls and future 
needs. Molecular Nutrition & Food 
Research. 2015;59:1274-1291
[206] Marx WM, Teleni L, McCarthy 
AL, Vitetta L, McKavanagh D, Thomson 
D, et al. Ginger (Zingiber officinale) 
and chemotherapy-induced nausea and 
vomiting: A systematic literature review. 
Nutrition Reviews. 2013;71:245-254
[207] Lin SR, Fu YS, Tsai MJ, Cheng H, 
Weng CF. Natural compounds from 
herbs that can potentially execute as 
autophagy inducers for cancer therapy. 
International Journal of Molecular 
Sciences. 2017;18:pii: E1412. DOI: 
10.3390/ijms18071412
[208] Ruela-de-Sousa RR, Fuhler 
GM, Blom N, Ferreira CV, Aoyama 
H, Peppelenbosch MP. Cytotoxicity 
of apigenin on leukemia cell lines: 
Pharmacognosy - Medicinal Plants
34
Implications for prevention and therapy. 
Cell Death & Disease. 2010;1:e19. DOI: 
10.1038/cddis.2009.18
[209] Tuorkey MJ. Molecular targets of 
luteolin in cancer. European Journal of 
Cancer Prevention. 2016;25:65-76
[210] Yang CS, Wang H. Cancer 
preventive activities of tea catechins. 
Molecules. 2016;21:pii: E1679
[211] Dybkowska E, Sadowska A, 
Świderski F, Rakowska R, Wysocka K. The 
occurrence of resveratrol in foodstuffs 
and its potential for supporting cancer 
prevention and treatment. A review. 
Roczniki Państwowego Zakładu Higieny. 
2018;69:5-14
[212] Bock PR, Hanisch J, Matthes H, 
Zänker KS. Targeting inflammation in 
cancer-related-fatigue: A rationale for 
mistletoe therapy as supportive care in 
colorectal cancer patients. Inflammation 
& Allergy Drug Targets. 2014;13:105-111
[213] Baliga MS, Rao S, Rai MP, D’souza P. 
Radioprotective effects of the Ayurvedic 
medicinal plant Ocimum sanctum 
Linn. (holy basil): A memoir. Journal 
of Cancer Research and Therapeutics. 
2016;12:20-27
[214] Baharvand M, Jafari S, Mortazavi H. 
Herbs in oral mucositis. Journal of 
Clinical and Diagnostic Research. 
2017;11:ZE05-ZE11
[215] Yu J, Wang C, Kong Q, Wu X, 
Lu JJ, Chen X. Recent progress in 
doxorubicin-induced cardiotoxicity and 
protective potential of natural products. 
Phytomedicine. 2018;40:125-139
[216] Chen H, Lin Z, Arnst KE, Miller DD, 
Li W. Tubulin inhibitor-based antibody-
drug conjugates for cancer therapy. 
Molecules. 2017;22:1281. DOI: 10.3390/
molecules22081281
[217] Shankar Babu M, Mahanta S, 
Lakhter AJ, Hato T, Paul S, Naidu 
SR. Lapachol inhibits glycolysis in 
cancer cells by targeting pyruvate kinase 
M2. PLoS One. 2018;13:e0191419. DOI: 
10.1371/journal.pone.0191419
[218] Khalili M, Akbarzadeh A, 
Chiani M, Sepideh T. The effect 
of nanoliposomal and pegylated 
nanoliposomal forms of 6-gingerol on 
breast cancer cells. Research Journal of 
Recent Sciences. 2013;2:29-33
[219] Cuendet M, Pezzuto JM. Antitumor 
activity of bruceantin: An old drug 
with new promise. Journal of Natural 
Products. 2004;67:269-272
[220] Guo Z, Vangapandu S, 
Sindelar RW, Walker LA, Sindelar 
RD. Biologically active quassinoids 
and their chemistry: Potential leads 
for drug design. Frontiers in Medicinal 
Chemistry. 2009;4:285-308
